Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
20 "Jin Ho Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Breast cancer
Impact of Postmastectomy Radiation Therapy on Breast Cancer Patients According to Pathologic Nodal Status after Modern Neoadjuvant Chemotherapy
Dowook Kim, Jin Ho Kim, In Ah Kim, Ji Hyun Chang, Kyung Hwan Shin
Cancer Res Treat. 2023;55(2):592-602.   Published online October 11, 2022
DOI: https://doi.org/10.4143/crt.2022.998
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The utility of postmastectomy radiation therapy (PMRT) for breast cancer patients after neoadjuvant chemotherapy (NAC) is highly controversial. This study evaluated the impact of PMRT according to pathologic nodal status after modern NAC.
Materials and Methods
We retrospectively reviewed 682 patients with clinical stage II-III breast cancer who underwent NAC and mastectomy from 2013 to 2017. In total, 596 patients (87.4%) received PMRT, and 86 (12.6%) did not. We investigated the relationships among locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), overall survival (OS), and various prognostic factors. Subgroup analyses were also performed to identify patients who may benefit from PMRT.
Results
The median follow-up duration was 67 months. In ypN+ patients (n=368, 51.2%), PMRT showed significant benefits in terms of LRRFS, DFS, and OS (all p < 0.001). In multivariate analyses, histologic grade (HG) III (p=0.002), lymphovascular invasion (LVI) (p=0.045), and ypN2-3 (p=0.02) were significant risk factors for poor LRRFS. In ypN1 patients with more than two prognostic factors among luminal/human epidermal growth factor receptor-2–negative subtype, HG I-II, and absence of LVI, PMRT had no significant effect on LRRFS (p=0.18). In ypN0 patients (n=351, 48.8%), PMRT was not significantly associated with LRRFS, DFS, or OS. However, PMRT showed better LRRFS in triple-negative breast cancer (TNBC) patients (p=0.03).
Conclusion
PMRT had a major impact on treatment outcomes in patients with residual lymph nodes following NAC and mastectomy. Among ypN0 patients, PMRT may be beneficial only for those with TNBC.

Citations

Citations to this article as recorded by  
  • Analysis of Individualized Silicone Rubber Bolus Using Fan Beam Computed Tomography in Postmastectomy Radiotherapy: A Dosimetric Evaluation and Skin Acute Radiation Dermatitis Survey
    Xue-mei Chen, Chen-di Xu, Li-ping Zeng, Xiao-tong Huang, Ao-qiang Chen, Lu Liu, Liu-wen Lin, Le-cheng Jia, Hua Li, Xiao-bo Jiang
    Technology in Cancer Research & Treatment.2024;[Epub]     CrossRef
  • Does Post-Mastectomy Radiotherapy Confer Survival Benefits on Patients With 1-3 Clinically Positive Lymph Nodes Rendered Pathologically Negative After Neoadjuvant Systemic Chemotherapy: Consensus from A Pooled Analysis?
    Munaser Alamoodi
    European Journal of Breast Health.2024; 20(2): 81.     CrossRef
  • Oncological outcomes of stage I–II breast cancer treatment after subcutaneous/skin-sparing mastectomies with reconstruction
    E. A. Rasskazova, A. D. Zikiryakhodzhaev
    MD-Onco.2024; 4(3): 37.     CrossRef
  • Effectiveness of mat pilates on fatigue in women with breast cancer submitted to adjuvant radiotherapy: randomized controlled clinical trial
    Daniele Medeiros Torres, Kelly de Menezes Fireman, Erica Alves Nogueira Fabro, Luiz Claudio Santos Thuler, Rosalina Jorge Koifman, Anke Bergmann, Sabrina da Silva Santos
    Supportive Care in Cancer.2023;[Epub]     CrossRef
  • The Role of Sentinel Lymph Node Biopsy in Breast Cancer Patients Who Become Clinically Node-Negative Following Neo-Adjuvant Chemotherapy: A Literature Review
    Giulia Ferrarazzo, Alberto Nieri, Emma Firpo, Andrea Rattaro, Alessandro Mignone, Flavio Guasone, Augusto Manzara, Giuseppe Perniciaro, Stefano Spinaci
    Current Oncology.2023; 30(10): 8703.     CrossRef
  • 5,740 View
  • 215 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Head and Neck cancer
Radiotherapy versus Surgery in Early-Stage HPV-Positive Oropharyngeal Cancer
Dong-Yun Kim, Hong-Gyun Wu, Jin Ho Kim, Joo Ho Lee, Soon-Hyun Ahn, Eun-Jae Chung, Keun-Yong Eom, Young Ho Jung, Woo-Jin Jeong, Tack-Kyun Kwon, Suzy Kim, Chan Woo Wee
Cancer Res Treat. 2022;54(2):406-416.   Published online June 23, 2021
DOI: https://doi.org/10.4143/crt.2021.441
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to compare the outcomes of primary radiotherapy (RT) versus surgery in early-stage human papilloma virus–positive oropharyngeal squamous cell carcinoma (hpv+OPC), and investigate the preoperative clinical factors that can predict the requirement for postoperative adjuvant treatment.
Materials and Methods
This multicenter study included 166 patients with American Joint Committee on Cancer 8th edition-Stages I-II hpv+OPC. Sixty (36.1%) and 106 (63.9%) patients underwent primary (concurrent chemo)radiotherapy [(CC)RT] and surgery, respectively. Seventy-eight patients (73.6%) in the surgery group received postoperative (CC)RT.
Results
With a median follow-up of 45.6 months for survivors, the 2-year overall survival (OS), progression-free survival (PFS), and locoregional control (LC) for RT/surgery were 97.8%/96.4%, 91.1%/92.0%, and 92.9%/93.3%, respectively. In multivariate analyses, patients with synchronous radiologic extranodal extension and conglomeration (ENEcong) of metastatic lymph nodes (LNs) showed significantly poorer OS (p=0.047), PFS (p=0.001), and LC (p=0.003). In patients undergoing primary surgery, two or more clinically positive LN metastases (odds ratio [OR], 5.15; p=0.004) and LN metastases with ENEcong (OR, 3.75; p=0.009) were predictors of postoperative chemoradiotherapy. No patient in the primary RT group demonstrated late severe toxicity whereas three (2.8%), one (0.9%), and one (0.9%) patient in the surgery group showed grade 3 dysphagia, grade 3 xerostomia, and fatal oral cavity bleeding.
Conclusion
We found no differences in OS, PFS, and LC between upfront RT and surgery in stage I-II hpv+OPC which warrants comparison through a prospective trial in the treatment de-escalation era. However, most early-stage hpv+OPC patients undergoing surgery received adjuvant (CC)RT. Pretreatment LN findings were prognostic and predictive for adjuvant treatment.

Citations

Citations to this article as recorded by  
  • Definitive radio(chemo)therapy versus upfront surgery in the treatment of HPV-related localized or locally advanced oropharyngeal squamous cell carcinoma
    Jérémy Baude, Caroline Guigou, David Thibouw, Noémie Vulquin, Mireille Folia, Guillaume Constantin, Jihane Boustani, Christian Duvillard, Sylvain Ladoire, Gilles Truc, Aurélie Bertaut, Cédric Chevalier, Scott M. Langevin
    PLOS ONE.2024; 19(7): e0307658.     CrossRef
  • INFLUENCE OF CONFORMAL RADIOTHERAPY IN COMBINATION WITH RADIOMODIFIERS ON THE CONTENT OF VEGF, COX-2, AND PGE-2 IN BLOOD SERUM OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA
    N. MITRYAYEVA, L. GREBINYK, S. ARTIUKH, N. BILOZOR, V. STARENKIY
    Experimental Oncology.2024; 46(3): 253.     CrossRef
  • Assessment of Radiologic Extranodal Extension Using Combinatorial Analysis of Nodal Margin Breakdown and Metastatic Burden in Oropharyngeal Cancer
    Sungryeal Kim, Hannah Park, Se Hyun Yeou, Jin Roh, Yoo Seob Shin, Chul-Ho Kim, Eun Ju Ha, Jeon Yeob Jang
    Cancers.2023; 15(13): 3276.     CrossRef
  • Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)
    Chun Wei, Xiaojun Lan, Maona Qiu, Ran Cui, Qiuxia Fu, Shafiu Umar Shinge, Tobias Muluh, Ou Jiang
    Oncology Letters.2023;[Epub]     CrossRef
  • 7,679 View
  • 219 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Genitourinary cancer
Prediction of Pathologic Findings with MRI-Based Clinical Staging Using the Bayesian Network Modeling in Prostate Cancer: A Radiation Oncologist Perspective
Chan Woo Wee, Bum-Sup Jang, Jin Ho Kim, Chang Wook Jeong, Cheol Kwak, Hyun Hoe Kim, Ja Hyeon Ku, Seung Hyup Kim, Jeong Yeon Cho, Sang Youn Kim
Cancer Res Treat. 2022;54(1):234-244.   Published online May 17, 2021
DOI: https://doi.org/10.4143/crt.2020.1221
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to develop a model for predicting pathologic extracapsular extension (ECE) and seminal vesicle invasion (SVI) while integrating magnetic resonance imaging-based T-staging (cTMRI, cT1c-cT3b).
Materials and Methods
A total of 1,915 who underwent radical prostatectomy between 2006-2016 met the inclusion/exclusion criteria. We performed a multivariate logistic regression analysis as well as Bayesian network (BN) modeling based on possible confounding factors. The BN model was internally validated using 5-fold validation.
Results
According to the multivariate logistic regression analysis, initial prostate-specific antigen (iPSA) (β=0.050, p < 0.001), percentage of positive biopsy cores (PPC) (β=0.033, p < 0.001), both lobe involvement on biopsy (β=0.359, p=0.009), Gleason score (β=0.358, p < 0.001), and cTMRI (β=0.259, p < 0.001) were significant factors for ECE. For SVI, iPSA (β=0.037, p < 0.001), PPC (β=0.024, p < 0.001), Gleason score (β=0.753, p < 0.001), and cTMRI (β=0.507, p < 0.001) showed statistical significance. BN models to predict ECE and SVI were also successfully established. The overall area under the receiver operating characteristic curve (AUC)/accuracy of the BN models were 0.76/73.0% and 0.88/89.6% for ECE and SVI, respectively. According to internal comparison between the BN model and Roach formula, BN model had improved AUC values for predicting ECE (0.76 vs. 0.74, p=0.060) and SVI (0.88 vs. 0.84, p < 0.001).
Conclusion
Two models to predict pathologic ECE and SVI integrating cTMRI were established and installed on a separate website for public access to guide radiation oncologists.

Citations

Citations to this article as recorded by  
  • Measurements of target volumes and organs at risk using DW‑MRI in patients with central lung cancer accompanied with atelectasis
    Xinli Zhang, Tong Liu, Hong Zhang, Mingbin Zhang
    Molecular and Clinical Oncology.2023;[Epub]     CrossRef
  • 6,361 View
  • 145 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Pediatric cancer
Absolute Neutrophil Count after the First Chemotherapy Cycle as a Surrogate Marker for Treatment Outcomes in Patients with Neuroblastoma
Ji Won Lee, Joon Seol Bae, Jin Ho Kim, Hee Won Cho, Hee Young Ju, Keon Hee Yoo, Hong Hoe Koo, Sook-young Woo, Seonwoo Kim, Ki Woong Sung
Cancer Res Treat. 2022;54(1):259-268.   Published online April 12, 2021
DOI: https://doi.org/10.4143/crt.2021.010
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We performed this study to determine whether the degree of neutropenia after the first chemotherapy cycle can be used as a surrogate marker of individual susceptibility to chemotherapeutic agents affecting treatment outcome in patients with neuroblastoma.
Materials and Methods
The study included 313 patients who received the first cycle chemotherapy with a CEDC (cisplatin+etoposide+doxorubicin+cyclophosphamide) regimen and had absolute neutrophil count (ANC) data available. The cumulative incidences of progression and treatment-related mortality (TRM) were estimated. To identify genetic variations associated with the ANC, a genome-wide association study (GWAS) was performed.
Results
An ANC of 32.5/μL was determined as the cutoff point to categorize patients into the good and poor prognosis subgroups in terms of progression. Patients with a high nadir ANC had a higher cumulative incidence of progression than those with a low nadir ANC (p < 0.001). In multivariate analysis, high nadir ANC, age, bone marrow involvement, and unfavorable histology were poor prognostic factors. With regard to the TRM, patients with a low nadir ANC (ANC < 51.0/μL) had a higher cumulative incidence of TRM than those with a high nadir ANC (p=0.010). In GWAS, single-nucleotide polymorphisms of LPHN2 and CRHR1 were significantly associated with the nadir ANC.
Conclusion
In neuroblastoma patients, the degree of neutropenia after the first chemotherapy cycle can be used as a surrogate marker to predict an individual’s susceptibility to chemotherapeutic agents. Tailoring of treatment based on the degree of neutropenia needs to be considered.

Citations

Citations to this article as recorded by  
  • Impact of 10% Dose Reductions and Duration of Treatment Delays in the Management of Chemotherapy‐Induced Neutropenia in Dogs Treated With Common Chemotherapy Protocols: A Single‐Centre Experience
    Suzanne Busser, Laura Blackwood, Constanza Pereira, Margo Chase‐Topping, Spela Bavcar, Quentin Fournier
    Veterinary and Comparative Oncology.2024; 22(4): 542.     CrossRef
  • Targeting the myeloid microenvironment in neuroblastoma
    Marjolein C. Stip, Loes Teeuwen, Miranda P. Dierselhuis, Jeanette H. W. Leusen, Daniëlle Krijgsman
    Journal of Experimental & Clinical Cancer Research.2023;[Epub]     CrossRef
  • 6,456 View
  • 163 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Head and Neck Cancer
Recent Treatment Patterns of Oropharyngeal Cancer in Korea Based on the Expert Questionnaire Survey of the Korean Society for Head and Neck Oncology (KSHNO)
Kyu Hye Choi, Jin Ho Song, Yeon-Sil Kim, Ji-hoon Kim, Woo-Jin Jeong, Inn-Chul Nam, Jin Ho Kim, Hee Kyung Ahn, Sang Hoon Chun, Hyun Jun Hong, Young-Hoon Joo, Young-Gyu Eun, Sung Ho Moon, Jeongshim Lee
Cancer Res Treat. 2021;53(4):1004-1014.   Published online January 29, 2021
DOI: https://doi.org/10.4143/crt.2020.973
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The incidence of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has increased, and staging and optimal therapeutic approaches are challenging. A questionnaire survey was conducted to investigate the controversial treatment policy of stage T2 OPC according to the N category and determine the opinions of multidisciplinary experts in Korea.
Materials and Methods
Five OPC scenarios were developed by the Subcommittee on Oropharyngeal Treatment Guidelines of the Korean Society for Head and Neck Oncology and distributed to experts of multidisciplinary treatment hospitals.
Results
Sixty-five experts from 45 institutions responded. For the HPV-positive T2N0M0 scenario, 67.7% of respondents selected surgery followed by definitive concurrent chemoradiotherapy (CCRT) or radiotherapy alone. For the T2N1M0 HPV-positive scenario, there was a notable difference in the selection of primary treatment by expert specialty; 53.9% of respondents selected surgery and 39.8% selected definitive CCRT as the primary treatment. For the T2N3M0 advanced HPV-positive scenario, 50.0% of respondents selected CCRT and 33.3% considered induction chemotherapy (IC) as the primary treatment. CCRT and IC were significantly more frequently selected for the HPV-related OPC cases (p=0.010). The interdepartmental variability showed that the head and neck surgeons and medical oncologists favored surgery, whereas the radiation oncologists preferably selected definitive CCRT (p < 0.001).
Conclusion
In this study, surgery was preferred for lymph node-negative OPC, and as lymph node metastasis progressed, CCRT tended to be preferred, and IC was administered. Clinical practice patterns by stage and HPV status showed differences according to expert specialty. Multidisciplinary consensus guidelines will be essential in the future.

Citations

Citations to this article as recorded by  
  • Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations
    Jeremy P Harris, Dylann K Fujimoto, Misako Nagasaka, Eric Ku, Garrett Harada, Hari Keshava, Ali Mahtabifard, Javier Longoria, Niral Patel, Steven Seyedin, Aaron Simon, Allen Chen
    Clinical Lung Cancer.2022; 23(4): 333.     CrossRef
  • Survey of radiation field and dose in human papillomavirus-positive oropharyngeal cancer: is de-escalation actually applied in clinical practice?
    Kyu Hye Choi, Jin Ho Song, Yeon-Sil Kim, Sung Ho Moon, Jeongshim Lee, Young-Taek Oh, Dongryul Oh, Jin Ho Kim, Jun Won Kim
    Radiation Oncology Journal.2021; 39(3): 174.     CrossRef
  • 6,324 View
  • 158 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
Clinical Outcomes of Postoperative Radiotherapy Following Radical Prostatectomy in Patients with Localized Prostate Cancer: A Multicenter Retrospective Study (KROG 18-01) of a Korean Population
Sung Uk Lee, Kwan Ho Cho, Won Park, Won Kyung Cho, Jae-Sung Kim, Chan Woo Wee, Young Seok Kim, Jin Ho Kim, Taek-Keun Nam, Jaeho Cho, Song Mi Jeong, Youngkyong Kim, Su Jung Shim, Youngmin Choi, Jun-Sang Kim
Cancer Res Treat. 2020;52(1):167-180.   Published online June 25, 2019
DOI: https://doi.org/10.4143/crt.2019.126
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the clinical outcomes of postoperative radiotherapy (PORT) patients who underwent radical prostatectomy for localized prostate cancer.
Materials and Methods
Localized prostate cancer patients who received PORT after radical prostatectomy between 2001 and 2012 were identified retrospectively in a multi-institutional database. In total, 1,117 patients in 19 institutions were included. Biochemical failure after PORT was defined as prostate-specific antigen (PSA) ≥ nadir+2 after PORT or initiation of androgen deprivation therapy (ADT) for increasing PSA regardless of its value.
Results
Ten-year biochemical failure-free survival, clinical failure-free survival, distant metastasisfree survival, overall survival (OS), and cause-specific survival were 60.5%, 76.2%, 84.4%, 91.1%, and 96.6%, respectively, at a median of 84 months after PORT. Pre-PORT PSA ≤ 0.5 ng/ml and Gleason’s score ≤ 7 predicted favorable clinical outcomes, with 10-year OS rates of 92.5% and 94.1%, respectively. The 10-year OS rate was 82.7% for patients with a PSA > 1.0 ng/mL and 86.0% for patients with a Gleason score of 8-10. The addition of longterm ADT (≥ 12 months) to PORT improved OS, particularly in those with a Gleason score of 8-10 or ≥ T3b.
Conclusion
Clinical outcomes of PORT in a Korean prostate cancer population were very similar to those in Western countries. Lower Gleason score and serum PSA level at the time of PORT were significantly associated with favorable outcomes. Addition of long-term ADT (≥ 12 months) to PORT should be considered, particularly in unfavorable risk patients with Gleason scores of 8-10 or ≥ T3b.

Citations

Citations to this article as recorded by  
  • Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer
    Sung Uk Lee, Jae-Sung Kim, Young Seok Kim, Jaeho Cho, Seo Hee Choi, Taek-Keun Nam, Song Mi Jeong, Youngkyong Kim, Youngmin Choi, Dong Eun Lee, Won Park, Kwan Ho Cho
    Cancer Research and Treatment.2022; 54(4): 1191.     CrossRef
  • A discussion on controversies and ethical dilemmas in prostate cancer screening
    Satish Chandra Mishra
    Journal of Medical Ethics.2021; 47(3): 152.     CrossRef
  • Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy
    Sung Uk Lee, Kwan Ho Cho, Jin Ho Kim, Young Seok Kim, Taek-Keun Nam, Jae-Sung Kim, Jaeho Cho, Seo Hee Choi, Su Jung Shim, Jin Hee Kim, Ah Ram Chang
    Technology in Cancer Research & Treatment.2021;[Epub]     CrossRef
  • 7,964 View
  • 209 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Impact of Regional Nodal Irradiation for Breast Cancer Patients with Supraclavicular and/or Internal Mammary Lymph Node Involvement: A Multicenter, Retrospective Study (KROG 16-14)
Kyubo Kim, Yuri Jeong, Kyung Hwan Shin, Jin Ho Kim, Seung Do Ahn, Su Ssan Kim, Chang-Ok Suh, Yong Bae Kim, Doo Ho Choi, Won Park, Jihye Cha, Mison Chun, Dong Soo Lee, Sun Young Lee, Jin Hee Kim, Hae Jin Park, Wonguen Jung
Cancer Res Treat. 2019;51(4):1500-1508.   Published online March 15, 2019
DOI: https://doi.org/10.4143/crt.2018.575
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate the treatment outcomes of radiotherapy (RT) for breast cancer with ipsilateral supraclavicular (SCL) and/or internal mammary (IMN) lymph node involvement.
Materials and Methods
A total of 353 patients from 11 institutions were included. One hundred and thirty-six patients had SCL involvement, 148 had IMN involvement, and 69 had both. All patients received neoadjuvant systemic therapy followed by breast-conserving surgery or mastectomy, and postoperative RT to whole breast/chest wall. As for regional lymph node irradiation, SCL RT was given to 344 patients, and IMN RT to 236 patients. The median RT dose was 50.4 Gy.
Results
The median follow-up duration was 61 months (range, 7 to 173 months). In-field progression was present in SCL (n=20) and/or IMN (n=7). The 5-year disease-free survival (DFS) and overall survival rates were 57.8% and 75.1%, respectively. On multivariate analysis, both SCL/IMN involvement, number of axillary lymph node ≥ 4, triple-negative subtype, and mastectomy were significant adverse prognosticators for DFS (p=0.022, p=0.001, p=0.001, and p=0.004, respectively). Regarding the impact of regional nodal irradiation, SCL RT dose ≥ 54 Gy was not associated with DFS (5-year rate, 52.9% vs. 50.9%; p=0.696) in SCL-involved patients, and the receipt of IMN RT was not associated with DFS (5-year rate, 56.1% vs. 78.1%; p=0.099) in IMN-involved patients.
Conclusion
Neoadjuvant chemotherapy followed by surgery and postoperative RT achieved an acceptable in-field regional control rate in patients with SCL and/or IMN involvement. However, a higher RT dose to SCL or IMN RT was not associated with the improved DFS in these patients.

Citations

Citations to this article as recorded by  
  • Clinical outcomes after post-operative radiotherapy for breast cancer patients presenting with ipsilateral supraclavicular metastasis: considerations on the cranial border of irradiation field
    Xiaofang Wang, Xiaomeng Zhang, Li Zhang, Jin Meng, Wei Shi, Xingxing Chen, Zhaozhi Yang, Xin Mei, Xiaoli Yu, Zhen Zhang, Zhimin Shao, Xiaomao Guo, Jinli Ma
    Breast Cancer.2025; 32(1): 144.     CrossRef
  • Internal mammary regional management after neoadjuvant therapy in breast cancer
    Zhao Bi, Chun-Hui Zheng, Tong-Yue Ren, Yong-Sheng Wang
    International Journal of Surgery.2024;[Epub]     CrossRef
  • Oncological outcomes in patients with residual triple-negative breast cancer after preoperative chemotherapy
    Hyunki Park, Haeyoung Kim, Won Park, Won Kyung Cho, Nalee Kim, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Sei Kyung Lee, Jai-Min Ryu
    Radiation Oncology Journal.2024; 42(3): 210.     CrossRef
  • Outcomes and Trends in Axillary Management of Stage cN3b Breast Cancer Patients
    Julia M. Selfridge, Zachary Schrank, Chris B. Agala, David W. Ollila, Kristalyn K. Gallagher, Dana L. Casey, Philip M. Spanheimer
    Annals of Surgical Oncology.2024;[Epub]     CrossRef
  • Clinical audit of breast cancer patients treated with helical tomotherapy for irradiation of the internal mammary chain
    Garima Shrivastav, Debanjali Datta, Tabassum Wadasadawala, Pallavi Rane, Subhajit Panda, Rima Pathak, Libin Scaria, Revathy Krishnamurthy, Rajiv Sarin
    Journal of Radiotherapy in Practice.2023;[Epub]     CrossRef
  • The optimal regional irradiation volume for breast cancer patients: A comprehensive systematic review and network meta-analysis of published studies
    Wei-Xiang Qi, Lu Cao, Cheng Xu, Gang Cai, Jiayi Chen
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Contemporary Outcomes After Multimodality Therapy in Patients With Breast Cancer Presenting With Ipsilateral Supraclavicular Node Involvement
    Kevin Diao, Lauren M. Andring, Carlos H. Barcenas, Puneet Singh, Huong (Carisa) Le-Petross, Valerie K. Reed, Jay P. Reddy, Elizabeth S. Bloom, Neelofur R. Ahmad, Lauren L. Mayo, George H. Perkins, Melissa P. Mitchell, Kevin T. Nead, Welela Tereffe, Benjam
    International Journal of Radiation Oncology*Biology*Physics.2022; 112(1): 66.     CrossRef
  • Locoregional Management and Prognostic Factors in Breast Cancer With Ipsilateral Internal Mammary and Axillary Lymph Node Involvement
    Lauren M. Andring, Kevin Diao, Susie Sun, Miral Patel, Gary J. Whitman, Pamela Schlembach, Isadora Arzu, Melissa M. Joyner, Simona F. Shaitelman, Karen Hoffman, Michael C. Stauder, Benjamin D. Smith, Wendy A. Woodward
    International Journal of Radiation Oncology*Biology*Physics.2022; 113(3): 552.     CrossRef
  • Yesterday, Today and Tomorrow – Are We Any Closer to Knowing Which Patients Will Benefit from Adjuvant Internal Mammary Nodal Irradiation?
    C.A. Johnson, J. Evans
    Clinical Oncology.2022; 34(8): 534.     CrossRef
  • Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study
    Haeyoung Kim, Yeon Jeong Kim, Donghyun Park, Woong-Yang Park, Doo Ho Choi, Won Park, Won kyung Cho, Nalee Kim
    Breast Cancer Research and Treatment.2021; 189(1): 167.     CrossRef
  • Cervical Lymph Node Involvement above the Supraclavicular Fossa in Breast Cancer: Comparison with Stage IIIC (KROG 18-02)
    Jae Sik Kim, Kyubo Kim, Kyung Hwan Shin, Jin Ho Kim, Seung Do Ahn, Su Ssan Kim, Yong Bae Kim, Jee Suk Chang, Doo Ho Choi, Won Park, Tae Hyun Kim, Mison Chun, Jihye Cha, Jin Hee Kim, Dong Soo Lee, Sun Young Lee, Hae Jin Park
    Journal of Breast Cancer.2020; 23(2): 194.     CrossRef
  • Aggressive Surgical Excision of Supraclavicular Lymph Node Did Not Improve the Outcomes of Breast Cancer With Supraclavicular Lymph Node Involvement (KROG 16-14)
    Kyubo Kim, Su Ssan Kim, Kyung Hwan Shin, Jin Ho Kim, Seung Do Ahn, Doo Ho Choi, Won Park, Sun Young Lee, Mison Chun, Jin Hee Kim, Yong Bae Kim, Jihye Cha, Hae Jin Park, Dong Soo Lee, Wonguen Jung
    Clinical Breast Cancer.2020; 20(1): 51.     CrossRef
  • Combined Therapy Can Improve the Outcomes of Breast Cancer with Isolated Supraclavicular Lymph Node Involvement


    Tianyi Ma, Yan Mao, Haibo Wang
    Cancer Management and Research.2020; Volume 12: 11857.     CrossRef
  • 8,495 View
  • 331 Download
  • 16 Web of Science
  • 13 Crossref
Close layer
The Feasibility of Spinal Stereotactic Radiosurgery for Spinal Metastasis with Epidural Cord Compression
Yi-Jun Kim, Jin Ho Kim, Kyubo Kim, Hak Jae Kim, Eui Kyu Chie, Kyung Hwan Shin, Hong-Gyun Wu, Il Han Kim
Cancer Res Treat. 2019;51(4):1324-1335.   Published online January 29, 2019
DOI: https://doi.org/10.4143/crt.2018.653
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to investigate the effectiveness and safety of spinal stereotactic radiosurgery (SRS) in treating spinal metastasis with epidural spinal cord compression (ESCC).
Materials and Methods
During 2013-2016, 149 regions of spinal metastasis in 105 patients treated with singlefraction (12-24 Gy) spinal SRS were reviewed. Cord compression of Bilsky grade 2 (with visible cerebrospinal fluid [CSF]) or 3 (no visible CSF) was defined as ESCC. Local progression (LP) and vertebral compression fracture (VCF) rates after SRS were evaluated using multivariate competing-risk regression analysis.
Results
The 1-year cumulative incidences of LP for Bilsky grades 0 (n=80), 1 (n=39), 2 (n=21), and 3 (n=9) were 3.0%, 8.4%, 0%, and 24.9%, respectively. Bilsky grade 2 ESCC did not significantly increase the LP rate (no LP for grade 2). The 1-year cumulative incidences of VCF for Bilsky grades 0, 1, 2, and 3 were 6.6%, 5.2%, 17.1%, and 12.1%, respectively. ESCC may increase VCF risk (subhazard ratio [SHR] for grade 2, 5.368; p=0.035; SHR for grade 3, 2.215; p=0.460). Complete or partial pain response rates after SRS were 79%, 78%, 53%, and 63% for Bilsky grades 0, 1, 2, and 3, respectively (p=0.008). No neurotoxicity of grade ≥ 3 was observed.
Conclusion
Spinal SRS for spinal metastasis with Bilsky grade 2 ESCC did not increase the LP rate, was not associated with severe neurotoxicity, and showed moderate VCF and pain response rates. Bilsky grade 3 had a high LP rate.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of SBRT for spine metastases: A systematic review and meta-analysis for preparation of an ESTRO practice guideline
    R.S. Guninski, F. Cuccia, F. Alongi, N. Andratschke, C. Belka, D. Bellut, M. Dahele, M. Josipovic, T.E. Kroese, P. Mancosu, G. Minniti, M. Niyazi, U Ricardi, P. Munck af Rosenschold, A. Sahgal, Y. Tsang, W.F.A.R. Verbakel, M. Guckenberger
    Radiotherapy and Oncology.2024; 190: 109969.     CrossRef
  • Metastatic Spinal Lesion with Minimal Epidural Compression: Surgical Treatment or Stereotactic Radiotherapy?
    O. I. Kit, D. E. Zakondyrin, A. A. Grin, E. E. Rostorguev, Y. V. Przhedetskiy, P. G. Sakun, V. I. Voshedskii, B. V. Matevosian, T. S. Shepelya
    Creative surgery and oncology.2024; 14(2): 127.     CrossRef
  • Surgical Interventions Following Radiotherapy in Spinal Metastases with Intermediate Instability: A Risk Factor Analysis: The Korean Society of Spinal Tumor Multicenter Study (KSST 2022-02)
    Se-Jun Park, Jin Ho Kim, Yong Chan Ahn, Woong Sub Koom, Hwa Kyung Byun, Young-Hoon Kim, Sang-Il Kim, Dong-Ho Kang
    Cancers.2024; 16(14): 2554.     CrossRef
  • Development of a novel 12-point grading system for evaluating epidural spinal cord compression and its clinical implications
    Xuyong Cao, Weihao Jiang, Xiongwei Zhao, Haikuan Yu, Mingxing Lei, Yuncen Cao, Xiuyun Su, Yaosheng Liu
    The Spine Journal.2023; 23(12): 1858.     CrossRef
  • Efficacy of Total En Bloc Spondylectomy versus Stereotactic Ablative Radiotherapy for Single Spinal Metastasis
    Dong-Ho Kang, Wooseok Lee, Bong-Soon Chang, Hyoungmin Kim, Sam Yeol Chang, Seong Hwa Hong, Jin Ho Kim, Hee Jung Son
    Cancers.2023; 15(23): 5518.     CrossRef
  • Radiomic modeling to predict risk of vertebral compression fracture after stereotactic body radiation therapy for spinal metastases
    Chengcheng Gui, Xuguang Chen, Khadija Sheikh, Liza Mathews, Sheng-Fu L. Lo, Junghoon Lee, Majid A. Khan, Daniel M. Sciubba, Kristin J. Redmond
    Journal of Neurosurgery: Spine.2022; 36(2): 294.     CrossRef
  • Stereotactic body radiotherapy for spinal metastases: a review
    Lanlan Guo, Lixin Ke, Ziyi Zeng, Chuanping Yuan, Ziwei Wu, Lei Chen, Lixia Lu
    Medical Oncology.2022;[Epub]     CrossRef
  • Treatment of Metastatic Spinal Disease; what the Radiologist needs to know
    Stephen Supple, Shahjehan Ahmad, Santhosh Gaddikeri, Miral D. Jhaveri
    The British Journal of Radiology.2022;[Epub]     CrossRef
  • Spinal metastases 2021: a review of the current state of the art and future directions
    Daniel M. Sciubba, Zach Pennington, Matthew W. Colman, C. Rory Goodwin, Ilya Laufer, Joshua C. Patt, Kristin J. Redmond, Philip Saylor, John H. Shin, Joseph H. Schwab, Andrew J. Schoenfeld
    The Spine Journal.2021; 21(9): 1414.     CrossRef
  • An updated algorithm for the treatment of spinal metastasis
    Kawngwoo Park, Seong Son, Sang Gu Lee, En Kyung Cho, Hee Kyung Ahn, In Keun Park, Sun Jin Sym, Young Saing Kim
    Journal of the Korean Society of Stereotactic and Functional Neurosurgery.2021; 17(2): 70.     CrossRef
  • Separation surgery for metastatic epidural spinal cord compression: A qualitative review
    Giuseppe Di Perna, Fabio Cofano, Cristina Mantovani, Serena Badellino, Nicola Marengo, Marco Ajello, Ludovico Maria Comite, Giuseppe Palmieri, Fulvio Tartara, Francesco Zenga, Umberto Ricardi, Diego Garbossa
    Journal of Bone Oncology.2020; 25: 100320.     CrossRef
  • Multidisciplinary management of metastatic spine disease: initial symptom-directed management
    Jeremy M Steinberger, Frank Yuk, Amish H Doshi, Sheryl Green, Isabelle M Germano
    Neuro-Oncology Practice.2020; 7(Supplement): i33.     CrossRef
  • 9,904 View
  • 232 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro
Hyeon Kang Koh, Soo Yeon Seo, Jin Ho Kim, Hak Jae Kim, Eui Kyu Chie, Seung-Ki Kim, Il Han Kim
Cancer Res Treat. 2019;51(2):696-705.   Published online August 13, 2018
DOI: https://doi.org/10.4143/crt.2018.249
AbstractAbstract PDFPubReaderePub
Purpose
Glioblastoma, the most common brain tumor in adults, has poor prognosis. The purpose of this study was to determine the effect of disulfiram (DSF), an aldehyde dehydrogenase inhibitor, on in vitro radiosensitivity of glioblastoma cells with different methylation status of O6-methylguanine-DNA methyltransferase (MGMT) promoter and the underlying mechanism of such effect.
Materials and Methods
Five human glioblastoma cells (U138MG, T98G, U251MG, U87MG, and U373MG) and one normal human astrocyte (NHA) cell were cultured and treated with DSF or 6MV X-rays (0, 2, 4, 6, and 8 Gy). For combined treatment, cells were treated with DSF before irradiation. Surviving fractions fit from cell survival based on colony forming ability. Apoptosis, DNA damage repair, and cell cycle distributionwere assayed bywestern blot for cleaved caspase-3, γH2AX staining, and flow cytometry, respectively.
Results
DSF induced radiosensitization in most of the glioblastoma cells, especially, in the cells with radioresistance as wildtype unmethylated promoter (MGMT-wt), but did not in normal NHA cell. DSF augmented or induced cleavage of caspase-3 in all cells after irradiation. DSF inhibited repair of radiation-induced DNA damage in MGMT-wt cells, but not in cells with methylated MGMT promoter. DSF abrogated radiation-induced G2/M arrest in T98G and U251MG cells.
Conclusion
Radiosensitivity of glioblastoma cells were preferentially enhanced by pre-irradiation DSF treatment compared to normal cell, especially radioresistant cells such as MGMT-wt cells. Induction of apoptosis or inhibition of DNA damage repair may underlie DSF-induced radiosensitization. Clinical benefit of combining DSF with radiotherapy should be investigated in the future.

Citations

Citations to this article as recorded by  
  • The role of KDM4A‐mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis
    Xi‐Xi Li, Jia‐Kun Xu, Wei‐Jie Su, Hong‐Lin Wu, Kun Zhao, Chang‐Ming Zhang, Xiang‐Kun Chen, Li‐Xuan Yang
    The Kaohsiung Journal of Medical Sciences.2024; 40(2): 161.     CrossRef
  • Glioblastoma Therapy: Past, Present and Future
    Elena Obrador, Paz Moreno-Murciano, María Oriol-Caballo, Rafael López-Blanch, Begoña Pineda, Julia Gutiérrez-Arroyo, Alba Loras, Luis Gonzalez-Bonet, Conrado Martinez-Cadenas, José Estrela, María Marqués-Torrejón
    International Journal of Molecular Sciences.2024; 25(5): 2529.     CrossRef
  • Exploring Disulfiram’s Anticancer Potential: PLGA Nano-Carriers for Prolonged Drug Delivery and Potential Improved Therapeutic Efficacy
    Ibrahim Dumbuya, Ana Maria Pereira, Ibrahim Tolaymat, Adnan Al Dalaty, Basel Arafat, Matt Webster, Barbara Pierscionek, Mouhamad Khoder, Mohammad Najlah
    Nanomaterials.2024; 14(13): 1133.     CrossRef
  • Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma
    Rafael Jiménez, Andrada Constantinescu, Muhube Yazir, Paula Alfonso-Triguero, Raquel Pequerul, Xavier Parés, Mileidys Pérez-Alea, Ana Paula Candiota, Jaume Farrés, Julia Lorenzo
    International Journal of Molecular Sciences.2024; 25(21): 11512.     CrossRef
  • Clinical, pharmacological, and formulation evaluation of disulfiram in the treatment of glioblastoma - a systematic literature review
    Beáta-Mária Benkő, Dimitrios A. Lamprou, Anna Sebestyén, Romána Zelkó, István Sebe
    Expert Opinion on Drug Delivery.2023; 20(4): 541.     CrossRef
  • Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma
    Katja Werlenius, Sara Kinhult, Tora Skeidsvoll Solheim, Henriette Magelssen, David Löfgren, Munila Mudaisi, Sofia Hylin, Jiri Bartek, Michael Strandéus, Magnus Lindskog, Havyan Bahroz Rashid, Louise Carstam, Sasha Gulati, Ole Solheim, Jiri Bartek, Øyvind
    JAMA Network Open.2023; 6(3): e234149.     CrossRef
  • Disulfiram/Copper induces antitumor activity against gastric cancer via the ROS/MAPK and NPL4 pathways
    Yao Liu, Xin Guan, Meiling Wang, Naixue Wang, Yutong Chen, Baolei Li, Zhuxuan Xu, Fangwei Fu, Cheng Du, Zhendong Zheng
    Bioengineered.2022; 13(3): 6579.     CrossRef
  • Disulfiram in glioma: Literature review of drug repurposing
    Shiyu Zhong, Shengyu Liu, Xin Shi, Xudong Zhang, Kunhang Li, Guojun Liu, Lishuai Li, Shanwei Tao, Bowen Zheng, Weichen Sheng, Ziyin Ye, Qichen Xing, Qingqing Zhai, Lijie Ren, Ying Wu, Yijun Bao
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Multimodal targeting of glioma with functionalized nanoparticles
    Hany E. Marei
    Cancer Cell International.2022;[Epub]     CrossRef
  • Formulation Comprising Arsenic Trioxide and Dimercaprol Enhances Radiosensitivity of Pancreatic Cancer Xenografts
    Renyan Tang, Jianmin Zhu, Ying Liu, Ning Wu, Jinbin Han
    Technology in Cancer Research & Treatment.2021;[Epub]     CrossRef
  • Antioxidant and Antiproliferative Activity of Finasteride against Glioblastoma Cells
    Hyeon Ji Kim, Tae-Jun Kim, Yu Gyung Kim, Chaeeun Seong, Jin-Hwa Cho, Wanil Kim, Kyung-Ha Lee, Do-Yeon Kim
    Pharmaceutics.2021; 13(9): 1410.     CrossRef
  • Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor
    Chan-Chuan Liu, Cheng-Lin Wu, Meng-Xuan Lin, Chun-I Sze, Po-Wu Gean
    International Journal of Molecular Sciences.2021; 22(19): 10496.     CrossRef
  • Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study
    Lisa Zirjacks, Nicolai Stransky, Lukas Klumpp, Lukas Prause, Franziska Eckert, Daniel Zips, Sabine Schleicher, Rupert Handgretinger, Stephan M. Huber, Katrin Ganser
    Biomolecules.2021; 11(11): 1561.     CrossRef
  • The combination of disulfiram and copper for cancer treatment
    Hong Li, Jingyu Wang, Chunfu Wu, Lihui Wang, Zhe-Sheng Chen, Wei Cui
    Drug Discovery Today.2020; 25(6): 1099.     CrossRef
  • Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme
    Jinyeong Choi, Gaeun Kim, Su Bin Cho, Hyung-Jun Im
    Journal of Nanobiotechnology.2020;[Epub]     CrossRef
  • Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma—Old Myth or New Logos?
    Francisco Meraz-Torres, Sarah Plöger, Claus Garbe, Heike Niessner, Tobias Sinnberg
    Cancers.2020; 12(12): 3538.     CrossRef
  • Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents
    Elmira Ekinci, Sagar Rohondia, Raheel Khan, Qingping P. Dou
    Recent Patents on Anti-Cancer Drug Discovery.2019; 14(2): 113.     CrossRef
  • 9,447 View
  • 297 Download
  • 20 Web of Science
  • 17 Crossref
Close layer
The Effect of Hospital Case Volume on Clinical Outcomes in Patients with Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Analysis (KROG-1106)
Boram Ha, Kwan Ho Cho, Sung Ho Moon, Chang-Geol Lee, Ki Chang Keum, Yeon-Sil Kim, Hong-Gyun Wu, Jin Ho Kim, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Jong Hoon Lee, Sung Hwan Kim, Won Taek Kim, Young-Taek Oh, Min Kyu Kang, Jin Hee Kim, Ji-Yoon Kim, Moon-June Cho, Chul Seoung Kay, Jin Hwa Choi
Cancer Res Treat. 2019;51(1):12-23.   Published online February 5, 2018
DOI: https://doi.org/10.4143/crt.2017.273
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the effect of hospital case volume on clinical outcomes in patients with nasopharyngeal carcinoma (NPC).
Materials and Methods
Data on 1,073 patients with cT1-4N0-3M0 NPC were collected from a multi-institutional retrospective database (KROG 11-06). All patients received definitive radiotherapy (RT) either with three-dimensional-conformal RT (3D-CRT) (n=576) or intensity-modulated RT (IMRT) (n=497). The patients were divided into two groups treated at high volume institution (HVI) (n=750) and low volume institution (LVI) (n=323), defined as patient volume ≥ 10 (median, 13; range, 10 to 18) and < 10 patients per year (median, 3; range, 2 to 6), respectively. Endpoints were overall survival (OS) and loco-regional progression-free survival (LRPFS).
Results
At a median follow-up of 56.7 months, the outcomes were significantly better in those treated at HVI than at LVI. For the 614 patients of propensity score-matched cohort, 5-year OS and LRPFS were consistently higher in the HVI group than in the LVI group (OS: 78.4% vs. 62.7%, p < 0.001; LRPFS: 86.2% vs. 65.8%, p < 0.001, respectively). According to RT modality, significant difference in 5-year OS was observed in patients receiving 3D-CRT (78.7% for HVI vs. 58.9% for LVI, p < 0.001) and not in those receiving IMRT (77.3% for HVI vs. 75.5% for LVI, p=0.170).
Conclusion
A significant relationship was observed between HVI and LVI for the clinical outcomes of patients with NPC. However, the difference in outcome becomes insignificant in the IMRT era, probably due to the standardization of practice by education.

Citations

Citations to this article as recorded by  
  • Accumulated Dose Deviation of Rotational and Residual Setup Errors on Nasopharyngeal Carcinoma Using MIM Treated by Helical Tomotherapy
    Wenyan Yao, Jiang Hu, Peixun Xu, Mengxue He, Yongwen Fang, Mingzhi Liu, Zongtai Li, Huilang He, Hui Liu, Wenzhao Sun, Senkui Xu
    Technology in Cancer Research & Treatment.2023;[Epub]     CrossRef
  • Systematic Review and Meta-analysis of the Association Between Radiation Therapy Treatment Volume and Patient Outcomes
    Jerry Ye Aung Kyaw, Alice Rendall, Erin F. Gillespie, Tom Roques, Laurence Court, Yolande Lievens, Alison C. Tree, Chris Frampton, Ajay Aggarwal
    International Journal of Radiation Oncology*Biology*Physics.2023; 117(5): 1063.     CrossRef
  • The Influence of Hospital Volume on the Outcomes of Nasopharyngeal, Sinonasal, and Skull-Base Tumors: A Systematic Review of the Literature
    Stephanie Flukes, Rahul K. Sharma, Shivangi Lohia, Marc A. Cohen
    Journal of Neurological Surgery Part B: Skull Base.2022; 83(03): 270.     CrossRef
  • A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma
    Khodayar Goshtasbi, Brandon M. Lehrich, Jack L. Birkenbeuel, Arash Abiri, Jeremy P. Harris, Edward C. Kuan
    Otolaryngology–Head and Neck Surgery.2021; 165(1): 93.     CrossRef
  • Hospital volume and physician volume in association with survival in patients with nasopharyngeal cancer after radiation therapy
    Tzu-Yu Lai, Chiu-Mei Yeh, Yu-Wen Hu, Chia-Jen Liu
    Radiotherapy and Oncology.2020; 151: 190.     CrossRef
  • 10,172 View
  • 215 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23
Kyubo Kim, Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Dae Yong Kim, Tae Hyun Kim, Jin Hee Kim, Jiyoung Kim
Cancer Res Treat. 2018;50(4):1316-1323.   Published online January 8, 2018
DOI: https://doi.org/10.4143/crt.2017.575
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study is to compare the treatment outcomes of breast conserving surgery (BCS) plus radiotherapy (RT) versus mastectomy for patients with pT1-2N1 triple-negative breast cancer (TNBC).
Materials and Methods
Using two multicenter retrospective studies on breast cancer, a pooled analysis was performed among 320 patients with pT1-2N1 TNBC. All patients who underwent BCS (n=212) receivedwhole breast RTwith orwithoutregional nodal RT,while nonewho underwent mastectomy (n=108)received it. All patients received taxane-based adjuvant chemotherapy. The median follow-up periods were 65 months in the BCS+RT group, and 74 months in the mastectomy group.
Results
The median age of all patients was 48 years (range, 24 to 70 years). Mastectomy group had more patients with multiple tumors (p < 0.001), no lymphovascular invasion (p=0.001), higher number of involved lymph node (p=0.028), and higher nodal ratio ≥ 0.2 (p=0.037). Other characteristics were not significantly different between the two groups. The 5-year locoregionalrecurrence-free, disease-free, and overall survivalrates of BCS+RT group versus mastectomy group were 94.6% versus 87.7%, 89.5% versus 80.4%, and 95.0% versus 87.8%, respectively, and the differences were statistically significant after adjusting for covariates (p=0.010, p=0.006, and p=0.005, respectively).
Conclusion
In pT1-2N1 TNBC, breast conservation therapy achieved better locoregional recurrencefree, disease-free, and overall survival rates compared with mastectomy.

Citations

Citations to this article as recorded by  
  • Breast conserving surgery combined with radiation therapy offers improved survival over mastectomy in early-stage breast cancer
    Elizaveta Vasilyeva, Alan Nichol, Brendan Bakos, Anise Barton, Michelle Goecke, Elaine Lam, Erin Martin, Caroline Lohrisch, Elaine McKevitt
    The American Journal of Surgery.2024; 231: 70.     CrossRef
  • Oncoplastic Breast Conservation for Central Tumors: Definition, Classification, and the Analysis of Single Institution Experience
    Andrii Zhygulin, Artem Fedosov
    Plastic and Reconstructive Surgery - Global Open.2024; 12(5): e5789.     CrossRef
  • Treatment Outcomes after Postoperative Radiotherapy in Triple-Negative Breast Cancer: Multi-Institutional Retrospective Study (KROG 17-05)
    Jin Kim, Sang Byun, Myeongsoo Kim, Kyung Shin, Dong Kim, Han Lee, Tae Kim, Yeon Kim, Yong Kim, Jee Chang, Kyubo Kim, Sun Lee
    Journal of Personalized Medicine.2024; 14(9): 941.     CrossRef
  • Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer
    Rajesh Pradhan, Anuradha Dey, Rajeev Taliyan, Anu Puri, Sanskruti Kharavtekar, Sunil Kumar Dubey
    Pharmaceutics.2023; 15(1): 246.     CrossRef
  • Breast-Conserving Therapy is Associated with Improved Survival Without an Increased Risk of Locoregional Recurrence Compared with Mastectomy in Both Clinically Node-Positive and Node-Negative Breast Cancer Patients
    Elizaveta Vasilyeva, Jeremy Hamm, Alan Nichol, Kathryn V. Isaac, Amy Bazzarelli, Carl Brown, Caroline Lohrisch, Elaine McKevitt
    Annals of Surgical Oncology.2023; 30(11): 6413.     CrossRef
  • Postmastectomy Radiation Therapy in Patients With Minimally Involved Lymph Nodes: A Review of the Current Data and Future Directions
    Bum-Sup Jang, Kyung Hwan Shin
    Journal of Breast Cancer.2022; 25(1): 1.     CrossRef
  • A Review of Current treatment for Triple-Negative Breast Cancer (TNBC)
    Wahyuni Wahyuni, Ajeng Diantini, Mohammad Ghozali, Sahidin I
    Research Journal of Pharmacy and Technology.2022; : 409.     CrossRef
  • Long non-coding RNA MRPS30 divergent transcript can be detected in the cytoplasm of triple-negative breast cancer cells and is targeted by microRNA-130b
    Dongtao Wang, Qiang Song, Tianyong Zhao, Fang Wang, Yang Yu, Jing Qi, Pengfei Lyu, Xiangyang Duan
    Bioengineered.2022; 13(3): 5954.     CrossRef
  • Breast-conserving surgery versus mastectomy for older women with triple-negative breast cancer: population-based study
    Waruiru Mburu, Shalini Kulasingam, James S Hodges, Beth A Virnig
    Journal of Comparative Effectiveness Research.2022; 11(13): 953.     CrossRef
  • Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer
    Yi-Zi Zheng, Yan Liu, Zhen-Han Deng, Guo-Wen Liu, Ni Xie
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Postoperative Radiotherapy Contributes to the Survival Benefit of Breast-Conserving Therapy over Mastectomy
    Chu-Ying Chen, Si-Yue Zheng, Gang Cai, Cheng Xu, Rong Cai, Min Li, Kun-Wei Shen, Xiao-Song Chen, Dan Ou, Wei-Xiang Qi, Lu Cao, Jia-Yi Chen, Weiren Luo
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Значення локорегіонарної терапії у хворих на тричі негативний рак грудної залози (огляд літератури)
    M.V. Pavlushenko, R.V. Liubota, R.I. Vereshchako, O.S. Zotov, M.F. Anikusko, I.I. Liubota
    Practical oncology.2022; 5(1): 23.     CrossRef
  • Breast conservation therapy confers survival and distant recurrence advantage over mastectomy for stage II Triple Negative Breast cancer
    Rebekah Macfie, Cynthia Aks, Kathryn Panwala, Nathalie Johnson, Jennifer Garreau
    The American Journal of Surgery.2021; 221(4): 809.     CrossRef
  • Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis
    A Fancellu, N Houssami, V Sanna, A Porcu, C Ninniri, M L Marinovich
    British Journal of Surgery.2021; 108(7): 760.     CrossRef
  • Are the Outcomes of Breast Conservation Surgery Inferior to Those of Mastectomy in Patients with Stage II-IIIA Triple-Negative Breast Cancer?
    Seungju Lee, Hyun Yul Kim, Youn Joo Jung, Hyun-June Paik, Dong-Il Kim, Chang Shin Jung, Seok-Kyung Kang, Jee Yeon Kim, Seokwon Lee, Youngtae Bae
    Journal of Breast Disease.2021; 9(2): 77.     CrossRef
  • Thrombin generation predicts early recurrence in breast cancer patients
    Marina Marchetti, Cinzia Giaccherini, Giovanna Masci, Cristina Verzeroli, Laura Russo, Luigi Celio, Roberta Sarmiento, Sara Gamba, Carmen J. Tartari, Erika Diani, Alfonso Vignoli, Paolo Malighetti, Daniele Spinelli, Nicole M. Kuderer, Federico Nichetti, M
    Journal of Thrombosis and Haemostasis.2020; 18(9): 2220.     CrossRef
  • Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams
    Francesco P. Cammarata, Giusi I. Forte, Giuseppe Broggi, Valentina Bravatà, Luigi Minafra, Pietro Pisciotta, Marco Calvaruso, Roberta Tringali, Barbara Tomasello, Filippo Torrisi, Giada Petringa, Giuseppe A. P. Cirrone, Giacomo Cuttone, Rosaria Acquaviva,
    International Journal of Molecular Sciences.2020; 21(17): 6337.     CrossRef
  • Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions
    Guang-Yi Sun, Ge Wen, Yu-Jing Zhang, Yu Tang, Hao Jing, Jian-Yang Wang, Jiang-Hu Zhang, Yong Yang, Xu-Ran Zhao, Si-Ye Chen, Jing Jin, Yong-Wen Song, Yue-Ping Liu, Hui Fang, Hua Ren, Yuan Tang, Shu-Nan Qi, Ning Li, Bo Chen, Ning-Ning Lu, Shu-Lian Wang, Ye-
    BMC Cancer.2020;[Epub]     CrossRef
  • Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases
    Stefanie Corradini, Daniel Reitz, Montserrat Pazos, Stephan Schönecker, Michael Braun, Nadia Harbeck, Christiane Matuschek, Edwin Bölke, Ute Ganswindt, Filippo Alongi, Maximilian Niyazi, Claus Belka
    Cancers.2019; 11(2): 160.     CrossRef
  • Are breast conservation treatment rates optimized for Asian women with symptomatic malignancies?
    Mona P. C. Tan, Yih Yiow Sitoh
    ANZ Journal of Surgery.2019; 89(5): 529.     CrossRef
  • 9,107 View
  • 221 Download
  • 16 Web of Science
  • 20 Crossref
Close layer
Incorporating Risk Factors to Identify the Indication of Post-mastectomy Radiotherapy in N1 Breast Cancer Treated with Optimal Systemic Therapy: A Multicenter Analysis in Korea (KROG 14-23)
Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Seung Do Ahn, Ja Young Kim, Won Park, Yong Bae Kim, Yeon-joo Kim, Jin Hee Kim, Kyubo Kim, Kyung Ran Park, Hyun Soo Shin, Bae Kwon Jeong, Sun Young Lee, Suzy Kim
Cancer Res Treat. 2017;49(3):739-747.   Published online October 19, 2016
DOI: https://doi.org/10.4143/crt.2016.405
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
In a recent meta-analysis, post-mastectomy radiotherapy (PMRT) reduced any first recurrence (AFR) and improved survival in N1 and N2 patients. We investigated risk factors for AFR in N1 after optimal systemic therapy without PMRT, to define a subgroup of patients who may benefit from PMRT.
Materials and Methods
One thousand three hundred eighty-two pT1-2N1M0 breast cancer patients treated with mastectomy without PMRT between 2005 and 2010 were retrospectively analyzed. Only 0.6% had no systemic therapy.
Results
After a median follow-up of 5.9 years, there were 173 AFR (53 loco-regional recurrence [LRR] without distant metastases [DM], 38 LRR with DM, and 82 DM without LRR). The 5-year LRR and AFR rates were 6.1% and 12.0%, respectively. Multivariate analysis revealed that close resection margin (p=0.001) was the only independent risk factor for LRR. Multivariate analysis for AFR revealed that age < 35 years (p=0.025), T2 stage (p=0.004), high tumor grade (p=0.032), close resection margin (p=0.035), and triple-negative biological subtype (p=0.031) were independent risk factors. Two or three positive lymph nodes (p=0.078) were considered a marginally significant factor. When stratified by these six factors, the 5-year LRR rates were 3.6% with 0-1 (n=606), 7.5% with 2-3 (n=655), and 12.7% with 4-6 (n=93) risk factors. The 5-year AFR rates were 7.1% with 0-1, 15.0% with 2-3, and 24.5% with 4-6 risk factors.
Conclusion
Patients with pT1-2N1M0 breast cancer who underwent mastectomy and optimal systemic therapy showed excellent loco-regional control and disease control. The patients with four or more risk factors may benefit from PMRT, and those with two or three risk factors merit consideration of PMRT.

Citations

Citations to this article as recorded by  
  • Clinical treatment score Post-5 Years (CTS5) predicts the benefit of postmastectomy radiotherapy in patients with T1-2N1 luminal breast cancer
    Ke Liu, Guan-Qiao Li, Si-Qi Li, Xue-Qin Chen, San-Gang Wu
    The Breast.2025; 79: 103873.     CrossRef
  • Who can benefit from postmastectomy radiotherapy among HR+/HER2- T1-2 N1M0 breast cancer patients? An explainable machine learning mortality prediction based approach
    Long Jin, Qifan Zhao, Shenbo Fu, Yuan Zhang, Shuhan Wu, Xiao Li, Fei Cao
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Assessment of Postmastectomy Radiation Therapy Receipt by Age and Association With Outcomes in Women With Breast Cancer
    Carolina E. Fasola, Elaina Graham, Wei Sha, Courtney R. Schepel, Sally J. Trufan, Anna Hecksher, Richard L. White, Lejla Hadzikadic-Gusic
    Clinical Breast Cancer.2024; 24(5): e396.     CrossRef
  • The significance of risk stratification through nomogram-based assessment in determining postmastectomy radiotherapy for patients diagnosed with pT1 − 2N1M0 breast cancer
    Chao Wei, Jie Kong, Huina Han, Xue Wang, Zimeng Gao, Danyang Wang, Andu Zhang, Jun Zhang, Zhikun Liu
    Radiation Oncology.2024;[Epub]     CrossRef
  • Development and validation of nomograms for predicting survival outcomes in patients with T1-2N1 breast cancer to identify those who could not benefit from postmastectomy radiotherapy
    Hongyu Pu, Yunbo Luo, Linxing Zhang, Xin Li, Fangwei Li, Jingtai Chen, Shuangqiang Qian, Yunhui Tang, Xiaobo Zhao, Lingmi Hou, Yanchun Gao
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Postmastectomy radiotherapy in patients with T1-2N1 breast cancer: a single center experience and a meta-analysis
    Meng Luo, Yao Jin, Chunjing Xu, Huihui Chen, Kun Zhang, Qiang Chen, Chencan Jin, Jinglu Lu, Jing Wang, Jia Huang, Hao Deng, Weili Jin, Shu Zheng, Yiding Chen, Jiaojiao Zhou
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 9979.     CrossRef
  • Developing prompts from large language model for extracting clinical information from pathology and ultrasound reports in breast cancer
    Hyeon Seok Choi, Jun Yeong Song, Kyung Hwan Shin, Ji Hyun Chang, Bum-Sup Jang
    Radiation Oncology Journal.2023; 41(3): 209.     CrossRef
  • The Role of Post-Mastectomy Radiotherapy in T1-2N1 Breast Cancer Patients: Propensity Score Matched Analysis
    Kangpyo Kim, Won Park, Haeyoung Kim, Won Kyung Cho, Nalee Kim, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu
    Cancers.2023; 15(22): 5473.     CrossRef
  • Immediate breast reconstruction has no impact on the oncologic outcomes of patients treated with post-mastectomy radiation therapy: a comparative analysis based on propensity score matching
    Nalee Kim, Haeyoung Kim, Won Park, Doo Ho Choi, Won Kyung Cho, Seok Jin Nam, Jeong Eon Lee, Seok Won Kim, Jonghan Yu, Sei Kyung Lee, Byung-Joon Jeon, Jai Kyong Pyon, Goo-Hyun Mun, Tae Gyu Kim
    Breast Cancer Research and Treatment.2022; 192(1): 101.     CrossRef
  • Postmastectomy Radiation Therapy in Patients With Minimally Involved Lymph Nodes: A Review of the Current Data and Future Directions
    Bum-Sup Jang, Kyung Hwan Shin
    Journal of Breast Cancer.2022; 25(1): 1.     CrossRef
  • Practical Model to Optimize the Strategy of Adjuvant Postmastectomy Radiotherapy in T1-2N1 Breast Cancer With Modern Systemic Therapy
    Fei-Fei Xu, Lu Cao, Cheng Xu, Gang Cai, Shu-Bei Wang, Wei-Xiang Qi, Jia-Yi Chen
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Influence of age as a continuous variable on the prognosis of patients with pT1-2N1 breast cancer
    Xu-Ran Zhao, Yu Tang, Hong-Fen Wu, Qi-Shuai Guo, Yu-Jing Zhang, Mei Shi, Jing Cheng, Hong-Mei Wang, Min Liu, Chang-Ying Ma, Ge Wen, Xiao-hu Wang, Hui Fang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Bo Chen, Shu-Nan Qi, Ning Li, Yuan Tang, Ning-Ning
    The Breast.2022; 66: 136.     CrossRef
  • Suggestion for the omission of post-mastectomy chest wall radiation therapy in patients who underwent skin-sparing/nipple-sparing mastectomy
    Nalee Kim, Won Park, Won Kyung Cho, Hae Young Kim, Doo Ho Choi, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Goo-Hyun Mun, Jai-Kyong Pyon, Byung-Joon Jeon
    The Breast.2022; 66: 54.     CrossRef
  • Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy
    Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
    BMC Cancer.2022;[Epub]     CrossRef
  • Risk factors to identify the indication for regional nodal irradiation in T1-2N1M0 breast cancer: A joint analysis of 4,243 real-world cases from two institutions
    Guang-Yi Sun, Ge Wen, Yu-Jing Zhang, Yu Tang, Hao Jing, Hui Fang, Jian-Yang Wang, Jiang-Hu Zhang, Xu-Ran Zhao, Si-Ye Chen, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Yuan Tang, Shu-Nan Qi, Ning Li, Bo Chen, Ning-Ning Lu, Ye-Xiong Li, Shu-Lian Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Prognostic factors for breast cancer patients with T1–2 tumors and 1–3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients
    Jia-ming Zhao, Qi An, Chao-nan Sun, Yu-bing Li, Zi-lan Qin, Hong Guo, Xue Zeng, Yao-tian Zhang, Lin-lin Wei, Ning Han, Shi-chen Sun, Na Zhang
    Breast Cancer.2021; 28(2): 298.     CrossRef
  • A Prognostic Risk Stratification Model to Identify Potential Population Benefiting From Postmastectomy Radiotherapy in T1–2 Breast Cancer With 1–3 Positive Axillary Lymph Nodes
    Niuniu Hou, Juliang Zhang, Lu Yang, Ying Wu, Zhe Wang, Mingkun Zhang, Li Yang, Guangdong Hou, Jianfeng Wu, Yidi Wang, Bingyao Dong, Lili Guo, Mei Shi, Rui Ling
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated
    Maria Cristina Leonardi, Ida Rosalia Scognamiglio, Patrick Maisonneuve, Samantha Dicuonzo, Damaris Patricia Rojas, Maria Alessia Zerella, Anna Morra, Marianna Alessandra Gerardi, Mattia Zaffaroni, Alessandra De Scalzi, Antonia Girardi, Francesca Magnoni,
    Breast Cancer Research and Treatment.2021; 188(2): 511.     CrossRef
  • Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
    Xiaofang Wang, Li Zhang, Xiaomeng Zhang, Jurui Luo, Xuanyi Wang, Xingxing Chen, Zhaozhi Yang, Xin Mei, Xiaoli Yu, Zhen Zhang, Xiaomao Guo, Zhimin Shao, Jinli Ma
    Breast Cancer Research and Treatment.2021; 190(2): 277.     CrossRef
  • Evaluation of the 8th edition of the American joint committee on cancer’s pathological staging system in prognosis assessment and treatment decision making for stage T1-2N1 breast cancer after mastectomy
    San-Gang Wu, Jun Wang, Chen-Lu Lian, Jian Lei, Li Hua, Qin Lin, Yong-Xiong Chen, Zhen-Yu He
    The Breast.2020; 51: 2.     CrossRef
  • Nomogram predicting survival as a selection criterion for postmastectomy radiotherapy in patients with T1 to T2 breast cancer with 1 to 3 positive lymph nodes
    Yu Tang, Yu-Jing Zhang, Na Zhang, Mei Shi, Ge Wen, Jing Cheng, Hong-Mei Wang, Min Liu, Xiao-Hu Wang, Qi-Shuai Guo, Hong-Fen Wu, Chang-Ying Ma, Jing Jin, Yue-Ping Liu, Yong-Wen Song, Hui Fang, Hua Ren, Shu-Lian Wang, Ye-Xiong Li
    Cancer.2020; 126(S16): 3857.     CrossRef
  • Effectiveness of the AJCC 8th edition staging system for selecting patients with T1–2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions
    Shulian Wang, Ge Wen, Yu Tang, Yong Yang, Hao Jing, Jianyang Wang, Jianghu Zhang, Xuran Zhao, Guangyi Sun, Jing Jin, Yongwen Song, Yueping Liu, Hui Fang, Yujing Zhang, Yexiong Li
    BMC Cancer.2020;[Epub]     CrossRef
  • Postmastectomy radiotherapy in T1-2 patients with one to three positive lymph nodes – Past, present and future
    Filip Kaššák, Christine Rossier, Cristina Picardi, Jacques Bernier
    The Breast.2019; 48: 73.     CrossRef
  • Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy
    Ji Hyun Chang, Kyung Hwan Shin, Seung Do Ahn, Hae Jin Park, Eui Kyu Chie, Jin Ho Kim, Su Ssan Kim, Yong Bae Kim, Won Park, Yeon-Joo Kim, Hyun Soo Shin, Jin Hee Kim, Sun Young Lee, Kyubo Kim, Kyung Ran Park, Bae Kwon Jeong, Ja Young Kim, Suzy Kim
    Breast Cancer Research and Treatment.2018; 169(3): 507.     CrossRef
  • Evaluation of the Benefit of Radiotherapy in Patients with Occult Breast Cancer: A Population-Based Analysis of the SEER Database
    Byoung Hyuck Kim, Jeanny Kwon, Kyubo Kim
    Cancer Research and Treatment.2018; 50(2): 551.     CrossRef
  • Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23
    Kyubo Kim, Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Dae Yong Kim, Tae Hyun Kim, Jin Hee Kim, Jiyoung Kim
    Cancer Research and Treatment.2018; 50(4): 1316.     CrossRef
  • Meeting Highlights: The Second Consensus Conference for Breast Cancer Treatment in Korea
    Seeyoun Lee, In Hae Park, Seho Park, Joohyuk Sohn, Joon Jeong, Sung Gwe Ahn, Ik Jae Lee, Hae Kyung Lee, Seung Ah Lee, Won Park, Kyung-Hun Lee, Sung-Won Kim, Sang-Ah Han, Kyung Hae Jung, Byung Ho Son
    Journal of Breast Cancer.2017; 20(3): 228.     CrossRef
  • Predicting loco-regional recurrence risk in T1, T2 breast cancer with 1–3 positive axillary nodes postmastectomy: Development of a predictive nomogram
    T Wadasadawala, S Kannan, S Gudi, A Rishi, A Budrukkar, V Parmar, T Shet, S Desai, S Gupta, R Badwe, R Sarin
    Indian Journal of Cancer.2017; 54(1): 352.     CrossRef
  • 11,458 View
  • 353 Download
  • 28 Web of Science
  • 28 Crossref
Close layer
Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization
Jin Ho Kim, Sung Ho Moon, Mina No, Jae Jin Kim, Eun Jung Choi, Bong Jun Cho, Jae Sung Kim, Il Han Kim, In Ah Kim
Cancer Res Treat. 2016;48(3):1130-1140.   Published online November 17, 2015
DOI: https://doi.org/10.4143/crt.2015.206
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Histone deacetylase (HDAC) inhibitors radiosensitize tumor cells. To elucidate mechanisms underlying radiosensitization by HDAC inhibition, understanding of differential contributions of HDAC isotypes is needed. The aim of this study was to investigate involvement of known HDAC isotypes in modulation of cellular radiosensitivity. Materials and Methods Because pharmacologic HDAC inhibitors lack isotype-specificity, RNA interference against 11 HDAC isotypes was used to inhibit HDAC in an isotype-specific manner. Radiation cell survival was evaluated using a clonogenic assay in SQ20B cells transfected with small interfering RNA specifically targeting HDAC isotypes. Immunocytochemistry was performed for detection of γH2AX foci. Protein expression was measured using Western blotting.
Results
Among 11 HDAC isotypes tested, specific inhibition of 7 isotypes (HDAC1, HDAC3, HDAC4, HDAC6, HDAC7, HDAC10, and HDAC11) enhanced radiation lethality in SQ20B cells. Radiosensitization by inhibition of these HDAC isotypes was accompanied by delay of DNA double strand break repair. Radiosensitivity of SQ20B cells was not altered by selective inhibition of the remaining four isotypes (HDAC2, HDAC5, HDAC8, and HDAC9). Inhibition of HDAC isotypes resulted in downregulation of various proteins involved in pro-survival and DNA damage repair pathways. Conclusion Isotype-specificity exists in HDAC inhibition-induced radiosensitization. Different HDAC isotypes are differentially involved in modulation of cellular radiosensitivity.

Citations

Citations to this article as recorded by  
  • Effects of a novel HDAC6-selective inhibitor’s radiosensitization on cancer cells
    Huixiao Hu, Qi Wang, Yuni Zhang, Shuhua Yang, Aihua Shen, Junfang Yan, Denggao Zhao, Burong Hu
    Molecular Biology Reports.2024;[Epub]     CrossRef
  • HDAC11: A novel target for improved cancer therapy
    Yan Liu, Xuechao Tong, Weina Hu, Da Chen
    Biomedicine & Pharmacotherapy.2023; 166: 115418.     CrossRef
  • Histone deacetylase 10, a potential epigenetic target for therapy
    Fajuan Cheng, Bin Zheng, Jianwei Wang, Guiting Zhao, Zhongshun Yao, Zhihong Niu, Wei He
    Bioscience Reports.2021;[Epub]     CrossRef
  • Synergistic Tumoricidal Effects of Alpha-Lipoic Acid and Radiotherapy on Human Breast Cancer Cells via HMGB1
    Hoon Sik Choi, Jin Hyun Kim, Si Jung Jang, Jeong Won Yun, Ki Mun Kang, Hojin Jeong, In Bong Ha, Bae Kwon Jeong
    Cancer Research and Treatment.2021; 53(3): 685.     CrossRef
  • HDAC11: a rising star in epigenetics
    Shan-Shan Liu, Fei Wu, Yue-Mei Jin, Wei- Qin Chang, Tian-Min Xu
    Biomedicine & Pharmacotherapy.2020; 131: 110607.     CrossRef
  • Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro
    Hyeon Kang Koh, Soo Yeon Seo, Jin Ho Kim, Hak Jae Kim, Eui Kyu Chie, Seung-Ki Kim, Il Han Kim
    Cancer Research and Treatment.2019; 51(2): 696.     CrossRef
  • Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [18F]TFAHA
    Maxwell T. Laws, Robin E. Bonomi, Swatabdi Kamal, David J. Gelovani, Jeremy Llaniguez, Shreya Potukutchi, Xin Lu, Thomas Mangner, Juri G. Gelovani
    Scientific Reports.2019;[Epub]     CrossRef
  • Mechanism of the Antitumor and Radiosensitizing Effects of a Manganese Porphyrin, MnHex-2-PyP
    Sung-Won Shin, Changhoon Choi, Ga-Haeng Lee, Arang Son, Su-Hyeon Kim, Hee Chul Park, Ines Batinic-Haberle, Won Park
    Antioxidants & Redox Signaling.2017; 27(14): 1067.     CrossRef
  • MicroRNA-200c increases radiosensitivity of human cancer cells with activated EGFR-associated signaling
    Taeryool Koo, Bong Jun Cho, Dan Hyo Kim, Ji Min Park, Eun Jung Choi, Hans H. Kim, David J Lee, In Ah Kim
    Oncotarget.2017; 8(39): 65457.     CrossRef
  • Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases
    Alokta Chakrabarti, Jelena Melesina, Fiona R Kolbinger, Ina Oehme, Johanna Senger, Olaf Witt, Wolfgang Sippl, Manfred Jung
    Future Medicinal Chemistry.2016; 8(13): 1609.     CrossRef
  • 12,478 View
  • 153 Download
  • 10 Web of Science
  • 10 Crossref
Close layer
In Vitro and In Vivo Radiosensitizing Effect of Valproic Acid on Fractionated Irradiation
Eui Kyu Chie, Jin Hee Shin, Jin Ho Kim, Hak Jae Kim, In Ah Kim, Il Han Kim
Cancer Res Treat. 2015;47(3):527-533.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.026
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted in order to validate the radiosensitization effect of valproic acid, a biologically available histone deacetylase inhibitor, for fractionated radiation.
Materials and Methods
Radiosensitization effect of valproic acid was tested for the A549 cell line and U87MG cell line in vitro. Fractionated irradiation of 12 Gy in four fractions was administered on D2-5 with valproic acid, 150 mg/Kg, ip, bid for six consecutive days (D1-6) to A549 and U87MG tumors implanted in BALB/c-nude mice. A growth delay curve was formulated.
Results
Radiosensitization effect of valproic acid was found for both cell lines; A549 at 1.5 mM and 3.0 mM concentration and U87MG at 3.0 mM concentration. In growth delay analysis, a statistically significant radiosensitization effect was observed for both tumors (p < 0.001 for both tumors). Difference for change in slope for control and valproic acid versus radiotherapy and radiotherapy plus valproic acid showed borderline significance for the U87MG cell line (p=0.065), indicating beyond additive effect, whereas this difference was statistically insignificant for A549 tumor (p=0.951), indicating additive effect.
Conclusion

Results
of this study indicate that a radiosensitizing effect for fractionated radiotherapy of valproic acid for A549 and U87MG tumors in vivo is evident and that it may be more than additive for U87MG tumors. Further exploitation of histone deacetylase inhibitors in clinical trials is warranted.

Citations

Citations to this article as recorded by  
  • Anti-epileptic drug use during adjuvant chemo-radiotherapy is associated with poorer survival in patients with glioblastoma: A nationwide population-based cohort study
    Peng-Yi Lee, Yu-Ting Wei, Kun-San Clifford Chao, Chin-Nan Chu, Wen-Hui Chung, Ti-Hao Wang*
    Journal of Cancer Research and Therapeutics.2024; 20(2): 555.     CrossRef
  • Valproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis
    Jessica K Sullivan, Paul P Fahey, Kinglsey E Agho, Simon P Hurley, Zhihui Feng, Richard O Day, David Lim
    Neuro-Oncology Practice.2023; 10(1): 13.     CrossRef
  • The function of histone methylation and acetylation regulators in GBM pathophysiology
    Colin McCornack, Timothy Woodiwiss, Angela Hardi, Hiroko Yano, Albert H. Kim
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Antitumor Activity of Non-thermal Atmospheric Pressure Plasma and Synergistic Effects of Hyperthermia
    TETSUO ADACHI
    Thermal Medicine.2022; 38(1): 1.     CrossRef
  • Epigenetic-Like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic Strategy
    Joerg Kotzerke, Dorothee Buesser, Anne Naumann, Roswitha Runge, Lisa Huebinger, Andrea Kliewer, Robert Freudenberg, Claudia Brogsitter
    Cancers.2022; 14(10): 2513.     CrossRef
  • Molecular Mechanisms Underlying Cellular Responses to the Loading of Non-thermal Atmospheric Pressure Plasma-activated Solutions
    Tetsuo Adachi
    YAKUGAKU ZASSHI.2021; 141(10): 1185.     CrossRef
  • Ability of plasma-activated acetated Ringer’s solution to induce A549 cell injury is enhanced by a pre-treatment with histone deacetylase inhibitors
    Tetsuo Adachi, Yumiko Matsuda, Rika Ishii, Tetsuro Kamiya, Hirokazu Hara
    Journal of Clinical Biochemistry and Nutrition.2020; 67(3): 232.     CrossRef
  • Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide
    Yu-Jen Kuo, Yao-Hsu Yang, I-Yun Lee, Pau-Chung Chen, Jen-Tsung Yang, Ting-Chung Wang, Martin Hsiu-Chu Lin, Wei-Hsun Yang, Chun-Yu Cheng, Kuo-Tai Chen, Wei-Chao Huang, Ming-Hsueh Lee
    Medicine.2020; 99(28): e21147.     CrossRef
  • Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
    Rashmi R. Shah, Peter D. Stonier
    Journal of Clinical Pharmacy and Therapeutics.2019; 44(1): 6.     CrossRef
  • Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation
    Jeong Il Yu, Changhoon Choi, Sung-Won Shin, Arang Son, Ga-Haeng Lee, Shin-Yeong Kim, Hee Chul Park
    Scientific Reports.2017;[Epub]     CrossRef
  • Histone deacetylase inhibitors stimulate the susceptibility of A549 cells to a plasma-activated medium treatment
    Tetsuo Adachi, Ayame Kano, Saho Nonomura, Tetsuro Kamiya, Hirokazu Hara
    Archives of Biochemistry and Biophysics.2016; 606: 120.     CrossRef
  • Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
    Caroline Happold, Thierry Gorlia, Olivier Chinot, Mark R. Gilbert, L. Burt Nabors, Wolfgang Wick, Stephanie L. Pugh, Monika Hegi, Timothy Cloughesy, Patrick Roth, David A. Reardon, James R. Perry, Minesh P. Mehta, Roger Stupp, Michael Weller
    Journal of Clinical Oncology.2016; 34(7): 731.     CrossRef
  • 11,637 View
  • 107 Download
  • 15 Web of Science
  • 12 Crossref
Close layer
A Survey of Stereotactic Body Radiotherapy in Korea
Sun Hyun Bae, Mi-Sook Kim, Won Il Jang, Chul-Seung Kay, Woochul Kim, Eun Seog Kim, Jin Ho Kim, Jin Hee Kim, Kwang Mo Yang, Kyu Chan Lee, A Ram Chang, Sunmi Jo
Cancer Res Treat. 2015;47(3):379-386.   Published online November 24, 2014
DOI: https://doi.org/10.4143/crt.2014.021
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to investigate the current status of stereotactic body radiotherapy (SBRT) in Korea. A nationwide survey was conducted by the Korean Stereotactic Radiosurgery Group of the Korean Society for Radiation Oncology (KROG 13-13).
Materials and Methods
SBRT was defined as radiotherapy with delivery of a high dose of radiation to an extracranial lesion in ≤ 4 fractions. A 16-questionnaire survey was sent by e-mail to the chief of radiation oncology at 85 institutions in June 2013.
Results
All institutions (100%) responded to this survey. Of these, 38 institutions (45%) have used SBRT and 47 institutions (55%) have not used SBRT. Regarding the treatment site, the lung (92%) and liver (76%) were the two most common sites. The most common schedules were 60 Gy/4 fractions for non-small cell lung cancer, 48 Gy/4 fractions for lung metastases, 60 Gy/3 fractions for hepatocellular carcinoma, and 45 Gy/3 fractions or 40 Gy/4 fractions for liver metastases. Four-dimensional computed tomography (CT) was the most common method for planning CT (74%). During planning CT, the most common method of immobilization was the use of an alpha cradle/vacuum-lock (42%).
Conclusion
Based on this survey, conduct of further prospective studies will be needed in order to determine the appropriate prescribed doses and to standardize the practice of SBRT.

Citations

Citations to this article as recorded by  
  • Five-Day Spacing of Two Fractionated Ablative Radiotherapies Enhances Antitumor Immunity
    Hyunkyung Kim, Eunju Lee, Haeun Cho, Eunji Kim, Won Il Jang, Kwangmo Yang, Yoon-Jin Lee, Tae-Jin Kim, Mi-Sook Kim
    International Journal of Radiation Oncology*Biology*Physics.2024; 118(2): 498.     CrossRef
  • Patterns of quality assurance and treatment planning for stereotactic body radiation therapy in India – A survey
    Smriti Sharma, Ritu Raj Upreti, Rajesh A. Kinhikar, G. Sahani, P. K. Dash Sharma
    Journal of Cancer Research and Therapeutics.2024; 20(6): 1752.     CrossRef
  • Measuring dose in lung identifies peripheral tumour dose inaccuracy in SBRT audit
    Maddison Shaw, Jessica Lye, Andrew Alves, Joerg Lehmann, Masoumeh Sanagou, Moshi Geso, Rhonda Brown
    Physica Medica.2023; 112: 102632.     CrossRef
  • Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium
    Mihir D Shanker, Howard Y Liu, Yoo Young Lee, Katherine A Stuart, Elizabeth E Powell, Alan Wigg, David I Pryor
    Journal of Gastroenterology and Hepatology.2021; 36(4): 873.     CrossRef
  • A national survey on technology and quality assurance for stereotactic body radiation therapy
    Carmelo Marino, Cristina Garibaldi, Ivan Veronese, Claudia Carbonini, Serenella Russo, Michele Stasi, Pietro Mancosu
    Physica Medica.2019; 65: 6.     CrossRef
  • Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07)
    Hyejung Cha, Hee Chul Park, Jeong Il Yu, Tae Hyun Kim, Taek-Keun Nam, Sang Min Yoon, Won Sup Yoon, Jun Won Kim, Mi Sook Kim, Hong Seok Jang, Youngmin Choi, Jin Hee Kim, Chul Seung Kay, Inkyung Jung, Jinsil Seong
    Cancer Research and Treatment.2017; 49(1): 61.     CrossRef
  • Application of stereotactic body radiation therapy to cancer liver metastasis
    Si-Yuan Zhang, Guang-Ying Zhu, Gong Li, Yi-Bao Zhang, Jian-Hao Geng
    Cancer Letters.2016; 379(2): 225.     CrossRef
  • Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group
    Sun Hyun Bae, Mi-Sook Kim, Won Il Jang, Chul-Seung Kay, Woochul Kim, Eun Seog Kim, Jin Ho Kim, Jin Hee Kim, Kwang Mo Yang, Kyu Chan Lee, A Ram Chang, Sunmi Jo
    Japanese Journal of Clinical Oncology.2016; 46(4): 363.     CrossRef
  • Radiotherapy in the multidisciplinary treatment of liver cancer: a survey on behalf of the Italian Association of Radiation Oncology
    Francesco Dionisi, Alessia Guarneri, Veronica Dell’Acqua, Mariacristina Leonardi, Rita Niespolo, Gabriella Macchia, Tiziana Comito, Maurizio Amichetti, Pierfrancesco Franco, Savino Cilla, Luciana Caravatta, Filippo Alongi, Giovanna Mantello
    La radiologia medica.2016; 121(9): 735.     CrossRef
  • 13,665 View
  • 101 Download
  • 11 Web of Science
  • 9 Crossref
Close layer
Sequence-Dependent Radiosensitization of Histone Deacetylase Inhibitors Trichostatin A and SK-7041
Jin Ho Kim, Il Han Kim, Jin Hee Shin, Hak Jae Kim, In Ah Kim
Cancer Res Treat. 2013;45(4):334-342.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.334
AbstractAbstract PDFPubReaderePub
PURPOSE
This preclinical study is to determine whether the capacity of histone deacetylase (HDAC) inhibitors to enhance radiation response depends on temporal sequences of HDAC inhibition and irradiation.
MATERIALS AND METHODS
The effects of HDAC inhibitors trichostatin A (TSA) and SK-7041 on radiosensitivity in human lung cancer cells were examined using a clonogenic assay, exposing cells to HDAC inhibitors in various sequences of HDAC inhibition and radiation. We performed Western blot of acetylated histone H3 and flow cytometry to analyze cell cycle phase distribution.
RESULTS
TSA and SK-7041 augmented radiation cell lethality in an exposure time-dependent manner when delivered before irradiation. The impact of TSA and SK-7041 on radiosensitivity rapidly diminished when HDAC inhibition was delayed after irradiation. Radiation induced the acetylation of histone H3 in cells exposed to TSA, while irradiation alone had no effect on the expression of acetylated histone H3 in TSA-naive cells. Preirradiation exposure to TSA abrogated radiation-induced G2/M-phase arrest. When delivered after irradiation, TSA had no effect on the peak of radiation-induced G2/M-phase arrest.
CONCLUSION
TSA and SK-7041 enhances radiosensitivity only when delivered before irradiation. Unless proven otherwise, it seems prudent to apply scheduling including preirradiation HDAC inhibition so that maximal radiosensitization is obtained.

Citations

Citations to this article as recorded by  
  • Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview
    Elsie Neo Seane, Shankari Nair, Charlot Vandevoorde, Anna Joubert
    Pharmaceuticals.2024; 17(5): 602.     CrossRef
  • Investigation of geroprotective and radioprotective effects of berberine and trichostatin A on the model of Drosophila melanogaster
    N. Ulyasheva, E. Proshkina, M. Shaposhnikov, A. Moskalev
    Proceedings of the Komi Science Centre of the Ural Division of the Russian Academy of Sciences.2023; 0(6): 93.     CrossRef
  • Low Dose of Trichostatin A Improves Radiation Resistance by Activating Akt/Nrf2-Dependent Antioxidation Pathway in Cancer Cells
    Fengqiu Zhang, Changsheng Shao, Zhu Chen, Yalin Li, Xumiao Jing, Qing Huang
    Radiation Research.2021;[Epub]     CrossRef
  • Time-sequential change in immune-related gene expression after irradiation in glioblastoma: next-generation sequencing analysis
    Yi-Jun Kim, Kwangsoo Kim, Soo Yeon Seo, Juyeon Yu, Il Han Kim, Hak Jae Kim, Chul-Kee Park, Kye Hwa Lee, Junjeong Choi, Myung Seon Song, Jin Ho Kim
    Animal Cells and Systems.2021; 25(4): 245.     CrossRef
  • Is level of acetylation directly correlated to radiation sensitivity of cancer cell?
    Fengqiu Zhang, Zhu Chen, Changsheng Shao, Qing Huang
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis.2019; 813: 13.     CrossRef
  • Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro
    Hyeon Kang Koh, Soo Yeon Seo, Jin Ho Kim, Hak Jae Kim, Eui Kyu Chie, Seung-Ki Kim, Il Han Kim
    Cancer Research and Treatment.2019; 51(2): 696.     CrossRef
  • Psammaplin A-Modified Novel Radiosensitizers for Human Lung Cancer and Glioblastoma Cells
    Chan Woo Wee, Jin Ho Kim, Hak Jae Kim, Hyun-Cheol Kang, Soo Youn Suh, Beom Soo Shin, Eunsook Ma, Il Han Kim
    Journal of Radiation Protection and Research.2019; 44(1): 15.     CrossRef
  • Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization
    Jin Ho Kim, Sung Ho Moon, Mina No, Jae Jin Kim, Eun Jung Choi, Bong Jun Cho, Jae Sung Kim, Il Han Kim, In Ah Kim
    Cancer Research and Treatment.2016; 48(3): 1130.     CrossRef
  • 12,611 View
  • 47 Download
  • 6 Web of Science
  • 8 Crossref
Close layer
The Role of Radiotherapy in the Treatment of Newly Diagnosed Supratentorial Low-grade Oligodendrogliomas: Comparative Analysis with Immediate Radiotherapy versus Surgery Alone
Hyun-Cheol Kang, Il Han Kim, Keun-Yong Eom, Jin Ho Kim, Hee-Won Jung
Cancer Res Treat. 2009;41(3):132-137.   Published online September 28, 2009
DOI: https://doi.org/10.4143/crt.2009.41.3.132
AbstractAbstract PDFPubReaderePub
Purpose

The purpose of this study was to evaluate the role of immediate postoperative radiotherapy (RT) in adult patients with a low-grade oligodendroglioma (LODG).

Materials and Methods

A total of 74 patients, older than 15 years, were treated in our institution between April 1990 and March 2006 for newly diagnosed LODGs. After surgery, 43 patients were treated with immediate RT with a total dose of 54~55.8 Gy with 1.8 Gy fractions (RT group) and 31 patients were followed with no adjuvant RT (OP group). All patients were closely observed until tumor progression or death with frequent work-ups including neurological examinations and MRI. Primary endpoints were overall survival and progression-free survival. The median follow-up duration of survivors was 6.2 years in the RT group and 5.8 years in the OP group.

Results

Median progression-free survival was 13.2 years in the RT group and 4.6 years in the OP group; multivariate analysis confirmed improved outcome with the use of immediate RT (hazard ratio, 0.22; 95% confidence interval-CI, 0.09~0.55; p<0.001). Median overall survival was 14.9 years in the RT group and 9.8 years in the OP group; the use of adjuvant RT was also associated with a trend toward better overall survival after immediate RT based on multivariate analysis (hazard ratio, 0.3; 95% CI, 0.08~1.17; p=0.082). No severe RT related complications were observed.

Conclusion

Immediate RT following surgery appears to be an effective treatment modality for supratentorial LODGs. However, the potential benefit of adjuvant RT for overall survival needs to be tested prospectively in the future.

Citations

Citations to this article as recorded by  
  • A systematic review and meta-analysis informing the role of adjuvant radiotherapy (RT) in Grade 2 and 3 oligodendroglioma
    Zhi Xuan Ng, Eng Siew Koh, Shing Fung Lee, Char Loo Tan, Kejia Teo, Andrea Wong, Simon S. Lo, Balamurugan Vellayappan
    Journal of Clinical Neuroscience.2024; 126: 247.     CrossRef
  • Oligodendrogliomas in Children: Clinical Experiences With 20 Patients
    Chieh-Tsai Wu, Pei-Kwei Tsay, Tang-Her Jaing, Shih-Hsiang Chen, Chen-Kan Tseng, Shih-Ming Jung
    Journal of Pediatric Hematology/Oncology.2016; 38(7): 555.     CrossRef
  • Oligodendroglial Tumors
    Kurt A. Jaeckle
    Seminars in Oncology.2014; 41(4): 468.     CrossRef
  • Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy
    Yasuo Iwadate, Tomoo Matsutani, Yuzo Hasegawa, Natsuki Shinozaki, Yoshinori Higuchi, Naokatsu Saeki
    Journal of Neuro-Oncology.2011; 102(3): 443.     CrossRef
  • 8,797 View
  • 52 Download
  • 4 Crossref
Close layer
A Histone Deacetylase Inhibitor, Trichostatin A, Enhances Radiosensitivity by Abrogating G2/M Arrest in Human Carcinoma Cells
In Ah Kim, Jin Ho Kim, Jin Hee Shin, Il Han Kim, Jae Sung Kim, Hong-Gyun Wu, Eui Kyu Chie, Yong Ho Kim, Bo-Kyung Kim, Semie Hong, Seok Won Park, Sung Whan Ha, Charn Il Park
Cancer Res Treat. 2005;37(2):122-128.   Published online April 30, 2005
DOI: https://doi.org/10.4143/crt.2005.37.2.122
AbstractAbstract PDFPubReaderePub
Purpose

Histone deacetylase inhibitors (HDIs) are emerging as potentially useful components in anticancer therapy. In this study, we tried to confirm the radiosensitizing effect of trichostatin A (TSA) on a panel of human carcinoma cell lines and elucidate its mechanism of interaction.

Materials and Methods

A549, HeLa and Caski cells were exposed to TSA for 18 hr prior to irradiation, and the cell survival then measured using a clonogenic assay. Western blot and flow cytometric analyses, for histone acetylation, and cell cycle and apoptosis, respectively, were also performed.

Results

TSA increased the acetylation of histone H3. The pretreatment of TSA consistently radiosensitized all three cell lines. The SF2 (surviving fraction at 2 Gy) of TSA-treated cells was significantly lower than that of mock treated cells. The SER (sensitizer enhancement ratio) increased in all 3 cell lines, in concentration dependent manners. The TSA treated cells showed abrogation of radiation-induced G2/M arrest, in a concentration dependent manner.

Conclusion

The pretreatment of TSA enhanced the radiosensitivity of a panel of human carcinoma cells, which was attributed, in part, to the abrogation of radiation-induced G2/M arrest.

Citations

Citations to this article as recorded by  
  • Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
    Yijun Xie, Di Xiao, Duo Li, Mei Peng, Wei Peng, Huaxin Duan, Xiaoping Yang
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Radiosensitizing effect of dendrosomal nanoformulation of curcumin on cancer cells
    Tahereh Jalali Varnamkhasti, Meisam Jafarzadeh, Majid Sadeghizadeh, Mahdi Aghili
    Pharmacological Reports.2022; 74(4): 718.     CrossRef
  • Pharmacological Properties of Trichostatin A, Focusing on the Anticancer Potential: A Comprehensive Review
    Abdelhakim Bouyahya, Nasreddine El Omari, Mohamed Bakha, Tarik Aanniz, Naoual El Menyiy, Naoufal El Hachlafi, Aicha El Baaboua, Mohamed El-Shazly, Mohammed Merae Alshahrani, Ahmed Abdullah Al Awadh, Learn-Han Lee, Taoufiq Benali, Mohammad S. Mubarak
    Pharmaceuticals.2022; 15(10): 1235.     CrossRef
  • Low Dose of Trichostatin A Improves Radiation Resistance by Activating Akt/Nrf2-Dependent Antioxidation Pathway in Cancer Cells
    Fengqiu Zhang, Changsheng Shao, Zhu Chen, Yalin Li, Xumiao Jing, Qing Huang
    Radiation Research.2021;[Epub]     CrossRef
  • Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
    Ying Li, Zhijun Zhan, Xuemin Yin, Shujun Fu, Xiyun Deng
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Is level of acetylation directly correlated to radiation sensitivity of cancer cell?
    Fengqiu Zhang, Zhu Chen, Changsheng Shao, Qing Huang
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis.2019; 813: 13.     CrossRef
  • Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
    Manuela Terranova-Barberio, Biagio Pecori, Maria Serena Roca, Serena Imbimbo, Francesca Bruzzese, Alessandra Leone, Paolo Muto, Paolo Delrio, Antonio Avallone, Alfredo Budillon, Elena Di Gennaro
    Journal of Experimental & Clinical Cancer Research.2017;[Epub]     CrossRef
  • Histone Acetylation Induced Transformation of B-DNA to Z-DNA in Cells Probed through FT-IR Spectroscopy
    Fengqiu Zhang, Qing Huang, Jingwen Yan, Zhu Chen
    Analytical Chemistry.2016; 88(8): 4179.     CrossRef
  • Cell-based multi-substrate assay coupled to UHPLC-ESI-MS/MS for a quick identification of class-specific HDAC inhibitors
    Vincent Zwick, Claudia Simões-Pires, Muriel Cuendet
    Journal of Enzyme Inhibition and Medicinal Chemistry.2016; 31(sup1): 209.     CrossRef
  • Assessment of the Effect of Trichostatin A on HeLa Cells through FT-IR Spectroscopy
    Fengqiu Zhang, Qing Huang, Jingwen Yan, Xin Zhang, Jianxin Li
    Analytical Chemistry.2015; 87(4): 2511.     CrossRef
  • Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
    Ahrum Min, Seock-Ah Im, Debora Keunyoung Kim, Sang-Hyun Song, Hee-Jun Kim, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J O’Connor, Yung-Jue Bang
    Breast Cancer Research.2015;[Epub]     CrossRef
  • CD44 is a biomarker associated with human prostate cancer radiation sensitivity
    WeiWei Xiao, Peter H. Graham, Carl A. Power, Jingli Hao, John H. Kearsley, Yong Li
    Clinical & Experimental Metastasis.2012; 29(1): 1.     CrossRef
  • Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells
    Han Sang Kim, Sang Cheol Kim, Sun Jeong Kim, Chan Hee Park, Hei-Cheul Jeung, Yong Bae Kim, Joong Bae Ahn, Hyun Cheol Chung, Sun Young Rha
    BMC Genomics.2012;[Epub]     CrossRef
  • In vivoRadiosensitization Effect of HDAC Inhibitor, SK-7041 on RIF-1 Cell Line
    Eui Kyu Chie, Jin Hee Shin, In Ah Kim, Il Han Kim
    The Journal of the Korean Society for Therapeutic Radiology and Oncology.2010; 28(4): 219.     CrossRef
  • Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6
    In Ah Kim, Mina No, Jang Mi Lee, Jin Hee Shin, Jee Sun Oh, Eun Jung Choi, Il Han Kim, Peter Atadja, Eric J. Bernhard
    Radiotherapy and Oncology.2009; 92(1): 125.     CrossRef
  • Histone Deacetylase Inhibitor–Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53
    In Ah Kim, Jin Hee Shin, Il Han Kim, Jin Ho Kim, Jae Sung Kim, Hong Gyun Wu, Eui Kyu Chie, Sung Whan Ha, Charn Il Park, Gary D. Kao
    Clinical Cancer Research.2006; 12(3): 940.     CrossRef
  • 12,459 View
  • 73 Download
  • 16 Crossref
Close layer
Treatment Outcome of Brain Metastasis after the Cranial Radiotherapy Followed by Fractionated Stereotactic Radiotherapy and Its Prognostic Factors
Hak Jae Kim, Semie Hong, Suzy Kim, Jin Ho Kim, Il Han Kim, Charn Il Park, Sung Whan Ha, Hong Gyun Wu, Wee Saing Kang
Cancer Res Treat. 2002;34(4):284-288.   Published online August 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.4.284
AbstractAbstract PDF
To evaluate the effectiveness of whole brain radiotherapy followed by stereotactic radiotherapy for newly diagnosed brain metastasis.
MATERIALS AND METHODS
Thirty-three metastatic brain tumors received radiotherapy to the whole brain and stereotactic radiotherapy in 25 patients. Lung carcinomas were the most common (17/25) primary tumor. The radiation dose was 30 to 40 Gy for the whole brain, with a 12 to 40 Gy boost to the metastatic foci. Survival and local control rates were determined, and the prognostic factors for survival were evaluated.
RESULTS
The overall median survival was 15 months and the actuarial survivals at 1- and 2-year were 67% and 31%, respectively. The local tumor control rate was 79%, with a median follow-up period of 9 months (2~36 months). The prognostic factors associated with survival were age, tumor size and the existence of active extracranial metastasis, with the performance status showing marginal significance. No acute or chronic complications were observed in the patients.
CONCLUSION
From our data, cranial radiotherapy followed by stereotactic radiotherapy was useful in the local control of metastatic tumors, and in the survival of patients with tumor factors, such as small size or the absence of extracranial tumor activity, and host factors, such as young age or good performance status.

Citations

Citations to this article as recorded by  
  • Prognostic Factors and Survival Outcome of Whole Brain Radiotherapy in Metastatic Brain Cancer- A Single Regional Cancer Centre Experience in North India
    Purnima Thakur, Aman Sharma, Manish Gupta, Anupama Dhiman, Jyoti Sharma
    Journal of Evolution of Medical and Dental Sciences.2019; 8(43): 3206.     CrossRef
  • Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
    Hee-Jun Kim, Seock-Ah Im, Bhumsuk Keam, Yu-Jung Kim, Sae-Won Han, Tae Min Kim, Do-Youn Oh, Jee Hyun Kim, Se-Hoon Lee, Eui Kyu Chie, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh, Dae Seog Heo, In Ae Park, Yung-Jue Bang, Sung Whan Ha
    Journal of Neuro-Oncology.2012; 106(2): 303.     CrossRef
  • 4,031 View
  • 27 Download
  • 2 Crossref
Close layer
Effect of Paclitaxol, Cisplatin, and 5-Flurouracil Chemotherapy in Advanced Stomach Cancer
Yeul Hong Kim, Sang Won Shin, Byung Soo Kim, Jin Ho Kim, Jong Kuk Kim, Young Jae Mok, Jong Suk Kim, Chi Wook Song, Ho Sang Ryu, Jun Suk Kim, Jin Hai Hyun
J Korean Cancer Assoc. 1997;29(4):648-655.
AbstractAbstract PDF
PURPOSE
Paclitaxel has not been used widely in gastrointestinal cancers. However, a recent phase II report of paclitaxel in patients with esophageal adenocarcinoma has suggested a possible role of paclitaxel for the treatment of advanced gastric carcinoma. A phase II trial was initiated to determine the clinical utility of a 3 drug combination (paclitaxel, cisplatin, and 5-fluorouracil) in patients with advanced gastric carcinoma.
MATERIALS AND METHODS
Eligibility included biopsy-proven inoperable or relapsed adenocarcinoma of the stomach with adequate bone marrow, hepatic, and renal function. Patients received paclitaxel at 175 mg/m2 (3 hour infusion) on day 1 followed by cisplatin at 20 mg/m2/day infusion and 5-fluorouracil at 750 mg/m2/day continuous infusion for 5 days. Treatment has been repeated in every 4 weeks. Total 31 patients were enrolled; 7 had relapsed disease after resection and 5-fluorouracil based adjuvant chemotherapy, 5 had previous chemotherapy. Twenty-one patients had measurable disease and 9 were evaluable. Demographics included; median age, 47 years (range, 27~64 years); male: female, 21: 10; median performance status 2 (range, 0~4).
RESULTS
Major responses occurred in 16/30 (53%; 95% confidence interval, 35~71%) patients (2 complete responses, 14 partial responses); 13 of 21 (61.9%) patients with measurable disease and 3 of 9 (33%) evaluable patients. Median response duration was 17 weeks (range, 8~44+ weeks) and median time to progression was 20 weeks (range, 8~51+ weeks). Median survival was 27 weeks (range, 8~72+ weeks). WHO grade 3~4 toxicities included: neutropenia (61.9%), nausea/vomiting (23.8%), mucositis (19%), and diarrhea (9.5%). Grade 2~3 neurotoxicity, fluid retention syndrome, hypersensitive reaction had occurred in 6, 2, and 1 patients, respectively. There was 1 instance of treatment-related death due to sepsis.
CONCLUSION
This regimen was highly active in advanced gastric carcinoma and had moderate toxicity. However, the response duration was short like other regimens. Considering poor performance status of our patients, this regimen may have strong potential in the neoadjuvant setting.
  • 3,315 View
  • 13 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP